WO2012055814A1 - Compound inducing lbpa accumulation for inhibiting cell-to-cell transmission of hiv - Google Patents
Compound inducing lbpa accumulation for inhibiting cell-to-cell transmission of hiv Download PDFInfo
- Publication number
- WO2012055814A1 WO2012055814A1 PCT/EP2011/068538 EP2011068538W WO2012055814A1 WO 2012055814 A1 WO2012055814 A1 WO 2012055814A1 EP 2011068538 W EP2011068538 W EP 2011068538W WO 2012055814 A1 WO2012055814 A1 WO 2012055814A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hiv
- cell
- cells
- compound
- progesterone
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 64
- 238000009825 accumulation Methods 0.000 title claims abstract description 37
- 230000001939 inductive effect Effects 0.000 title claims abstract description 28
- 230000005540 biological transmission Effects 0.000 title claims abstract description 24
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 23
- 210000004027 cell Anatomy 0.000 claims abstract description 241
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 116
- 210000002487 multivesicular body Anatomy 0.000 claims abstract description 73
- 208000015181 infectious disease Diseases 0.000 claims abstract description 33
- 238000011282 treatment Methods 0.000 claims abstract description 26
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims abstract description 14
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 claims abstract description 11
- 229940124411 anti-hiv antiviral agent Drugs 0.000 claims abstract description 10
- 230000002265 prevention Effects 0.000 claims abstract description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 188
- 229960003387 progesterone Drugs 0.000 claims description 94
- 239000000186 progesterone Substances 0.000 claims description 94
- KWKZCGMJGHHOKJ-ZKWNWVNESA-N Methyl Arachidonyl Fluorophosphonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCP(F)(=O)OC KWKZCGMJGHHOKJ-ZKWNWVNESA-N 0.000 claims description 76
- 102100037611 Lysophospholipase Human genes 0.000 claims description 34
- 108010058864 Phospholipases A2 Proteins 0.000 claims description 31
- 239000003112 inhibitor Substances 0.000 claims description 29
- 208000031886 HIV Infections Diseases 0.000 claims description 17
- 210000004698 lymphocyte Anatomy 0.000 claims description 14
- 210000002540 macrophage Anatomy 0.000 claims description 14
- 208000037357 HIV infectious disease Diseases 0.000 claims description 13
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 13
- 210000001616 monocyte Anatomy 0.000 claims description 13
- BYUCSFWXCMTYOI-ZRDIBKRKSA-N Bromoenol lactone Chemical compound O=C1OC(=C/Br)/CCC1C1=CC=CC2=CC=CC=C12 BYUCSFWXCMTYOI-ZRDIBKRKSA-N 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 9
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 7
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 7
- PLWROONZUDKYKG-DOFZRALJSA-N AACOCF3 Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)C(F)(F)F PLWROONZUDKYKG-DOFZRALJSA-N 0.000 claims description 6
- XSCZRVUQXBBTRO-GYCZXHFISA-N n-[[(2s,4r)-1-[2-(2,4-difluorobenzoyl)benzoyl]-4-tritylsulfanylpyrrolidin-2-yl]methyl]-4-[(z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]benzamide Chemical compound FC1=CC(F)=CC=C1C(=O)C1=CC=CC=C1C(=O)N1[C@H](CNC(=O)C=2C=CC(\C=C/3C(NC(=O)S\3)=O)=CC=2)C[C@@H](SC(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C1 XSCZRVUQXBBTRO-GYCZXHFISA-N 0.000 claims description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 6
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 5
- 230000004927 fusion Effects 0.000 claims description 5
- 239000002850 integrase inhibitor Substances 0.000 claims description 5
- 229940124524 integrase inhibitor Drugs 0.000 claims description 5
- 229940124264 Sigma 1 receptor antagonist Drugs 0.000 claims description 4
- 230000035800 maturation Effects 0.000 claims description 4
- ZXUYYZPJUGQHLQ-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl]-1-butanol Chemical compound C=1C=C(F)C=CC=1C(O)CCCN(CC1)CCN1C1=NC=C(F)C=N1 ZXUYYZPJUGQHLQ-UHFFFAOYSA-N 0.000 claims description 3
- SUIZRDJCBVPASY-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine Chemical compound C1CN(C)CCN1CCC1=CC=C(Cl)C(Cl)=C1 SUIZRDJCBVPASY-UHFFFAOYSA-N 0.000 claims description 3
- NXFDBTLQOARIMH-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine;dihydrochloride Chemical compound Cl.Cl.C1CN(C)CCN1CCC1=CC=C(Cl)C(Cl)=C1 NXFDBTLQOARIMH-UHFFFAOYSA-N 0.000 claims description 3
- KFJOAXDOAYZVOY-UHFFFAOYSA-N 2-[2-methyl-3-oxamoyl-1-[(2-phenylphenyl)methyl]indol-4-yl]oxyacetic acid Chemical compound CC1=C(C(=O)C(N)=O)C2=C(OCC(O)=O)C=CC=C2N1CC1=CC=CC=C1C1=CC=CC=C1 KFJOAXDOAYZVOY-UHFFFAOYSA-N 0.000 claims description 3
- WDVOBWSBTAJYAL-UHFFFAOYSA-N 3-[2-ethyl-1-oxamoyl-3-[(2-phenylphenyl)methyl]indolizin-8-yl]oxypropanoic acid Chemical compound N12C=CC=C(OCCC(O)=O)C2=C(C(=O)C(N)=O)C(CC)=C1CC1=CC=CC=C1C1=CC=CC=C1 WDVOBWSBTAJYAL-UHFFFAOYSA-N 0.000 claims description 3
- ZHGMDXSHODHWHV-UHFFFAOYSA-N N-{2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethyl}-N-propylpropan-1-amine hydrochloride Chemical compound Cl.CCCN(CCC)CCC1=CC=C(OC)C(OCCC=2C=CC=CC=2)=C1 ZHGMDXSHODHWHV-UHFFFAOYSA-N 0.000 claims description 3
- 229940122490 Sigma receptor antagonist Drugs 0.000 claims description 3
- 229960003878 haloperidol Drugs 0.000 claims description 3
- LPMIMPZUXJWRJJ-UHFFFAOYSA-N n,n-diethyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethanamine;hydron;chloride Chemical compound Cl.CCN(CC)CCC1=CC=C(OC)C(OCCC=2C=CC=CC=2)=C1 LPMIMPZUXJWRJJ-UHFFFAOYSA-N 0.000 claims description 3
- OBIPTWMZQPZWHN-QPPIDDCLSA-N n-[[(2s,4r)-1-[2-(2,4-difluorobenzoyl)benzoyl]-4-[2-methylpropyl-[(2-phenylphenyl)methyl]amino]pyrrolidin-2-yl]methyl]-3-[4-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl]prop-2-enamide Chemical compound CC(C)CN([C@H]1CN([C@H](CNC(=O)C=CC=2C=CC(C=C3C(NC(=O)S3)=O)=CC=2)C1)C(=O)C=1C(=CC=CC=1)C(=O)C=1C(=CC(F)=CC=1)F)CC1=CC=CC=C1C1=CC=CC=C1 OBIPTWMZQPZWHN-QPPIDDCLSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 62
- 230000000694 effects Effects 0.000 description 48
- 241000700605 Viruses Species 0.000 description 37
- 235000012000 cholesterol Nutrition 0.000 description 30
- 230000003834 intracellular effect Effects 0.000 description 25
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 21
- 150000002632 lipids Chemical class 0.000 description 20
- 230000003612 virological effect Effects 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 14
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000009826 distribution Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000012202 endocytosis Effects 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000003358 phospholipase A2 inhibitor Substances 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- 229960002555 zidovudine Drugs 0.000 description 11
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 11
- 238000007792 addition Methods 0.000 description 10
- 230000010076 replication Effects 0.000 description 10
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 9
- 229960004525 lopinavir Drugs 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 229920002307 Dextran Polymers 0.000 description 8
- 230000034303 cell budding Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000011002 quantification Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 229930182558 Sterol Natural products 0.000 description 7
- 230000034701 macropinocytosis Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 150000003432 sterols Chemical class 0.000 description 7
- 235000003702 sterols Nutrition 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 6
- 210000001163 endosome Anatomy 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229930183931 Filipin Natural products 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 4
- 230000036436 anti-hiv Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000012054 celltiter-glo Methods 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- IMQSIXYSKPIGPD-NKYUYKLDSA-N filipin Chemical compound CCCCC[C@H](O)[C@@H]1[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@H](O)\C(C)=C\C=C\C=C\C=C\C=C\[C@H](O)[C@@H](C)OC1=O IMQSIXYSKPIGPD-NKYUYKLDSA-N 0.000 description 4
- 229950000152 filipin Drugs 0.000 description 4
- IMQSIXYSKPIGPD-UHFFFAOYSA-N filipin III Natural products CCCCCC(O)C1C(O)CC(O)CC(O)CC(O)CC(O)CC(O)CC(O)C(C)=CC=CC=CC=CC=CC(O)C(C)OC1=O IMQSIXYSKPIGPD-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 241001263478 Norovirus Species 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 239000007980 Sørensen’s phosphate buffer Substances 0.000 description 3
- 230000008436 biogenesis Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 229960003920 cocaine Drugs 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 230000002121 endocytic effect Effects 0.000 description 3
- 230000004651 endocytosis pathway Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000003169 placental effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- AFGDPPHTYUQKOF-QAGGRKNESA-N (8r,9s,10r,13s,14s)-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 AFGDPPHTYUQKOF-QAGGRKNESA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 101000971351 Homo sapiens KRR1 small subunit processome component homolog Proteins 0.000 description 2
- 102100022339 Integrin alpha-L Human genes 0.000 description 2
- 102100021559 KRR1 small subunit processome component homolog Human genes 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 2
- 101710149136 Protein Vpr Proteins 0.000 description 2
- 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 description 2
- 101710104750 Sigma non-opioid intracellular receptor 1 Proteins 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 229960004748 abacavir Drugs 0.000 description 2
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 229960003804 efavirenz Drugs 0.000 description 2
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 2
- 229960002049 etravirine Drugs 0.000 description 2
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000004322 lipid homeostasis Effects 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 230000031852 maintenance of location in cell Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229960000689 nevirapine Drugs 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- CNPVJJQCETWNEU-CYFREDJKSA-N (4,6-dimethyl-5-pyrimidinyl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-1-piperazinyl]-4-methyl-1-piperidinyl]methanone Chemical compound N([C@@H](COC)C=1C=CC(=CC=1)C(F)(F)F)([C@H](C1)C)CCN1C(CC1)(C)CCN1C(=O)C1=C(C)N=CN=C1C CNPVJJQCETWNEU-CYFREDJKSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 206010003581 Asymptomatic HIV infection Diseases 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- 101100028791 Caenorhabditis elegans pbs-5 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101710202144 Capsid polyprotein Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- BDCFUHIWJODVNG-UHFFFAOYSA-N Desmosterol Natural products C1C=C2CC(O)C=CC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 BDCFUHIWJODVNG-UHFFFAOYSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- 108010032976 Enfuvirtide Proteins 0.000 description 1
- 238000001134 F-test Methods 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000584785 Homo sapiens Ras-related protein Rab-7a Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- 206010069803 Injury associated with device Diseases 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 108020002496 Lysophospholipase Proteins 0.000 description 1
- 102000019218 Mannose-6-phosphate receptors Human genes 0.000 description 1
- 108050006616 Mannose-6-phosphate receptors Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 208000008071 Parvoviridae Infections Diseases 0.000 description 1
- 206010057343 Parvovirus infection Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229940123898 Phospholipase A2 inhibitor Drugs 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000028677 Rab9 Human genes 0.000 description 1
- 108050007276 Rab9 Proteins 0.000 description 1
- 102100030019 Ras-related protein Rab-7a Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- YJEJKUQEXFSVCJ-WRFMNRASSA-N bevirimat Chemical compound C1C[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C YJEJKUQEXFSVCJ-WRFMNRASSA-N 0.000 description 1
- 229950002892 bevirimat Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- JIJWRJCVLPNOHM-UHFFFAOYSA-N bromo(phenyl)methanol Chemical compound OC(Br)C1=CC=CC=C1 JIJWRJCVLPNOHM-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960005107 darunavir Drugs 0.000 description 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- AVSXSVCZWQODGV-DPAQBDIFSA-N desmosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC=C(C)C)C)[C@@]1(C)CC2 AVSXSVCZWQODGV-DPAQBDIFSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960003586 elvitegravir Drugs 0.000 description 1
- JUZYLCPPVHEVSV-LJQANCHMSA-N elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 description 1
- 229960000366 emtricitabine Drugs 0.000 description 1
- 229960002062 enfuvirtide Drugs 0.000 description 1
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960003142 fosamprenavir Drugs 0.000 description 1
- MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940125777 fusion inhibitor Drugs 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000004020 intracellular membrane Anatomy 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960004710 maraviroc Drugs 0.000 description 1
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 description 1
- 230000008172 membrane trafficking Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000018352 negative regulation of endocytosis Effects 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229940042404 nucleoside and nucleotide reverse transcriptase inhibitor Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229960004742 raltegravir Drugs 0.000 description 1
- CZFFBEXEKNGXKS-UHFFFAOYSA-N raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000783 smooth endoplasmic reticulum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000003274 steroid hormone receptor blocking agent Substances 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229950009860 vicriviroc Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
Definitions
- the present invention concerns a compound inducing Lyso-Bis Phosphatidic Acid (LBPA), also named Bis(Monoacylglycero)Phosphate (BMP), accumulation in multivesicular bodies (MVB) of a cell for use for inhibiting i) cell-to-cell transmission of a Human Immunodeficiency Virus (HIV), and/or ii) entry of HIV into a cell, in an individual in need thereof.
- LBPA Lyso-Bis Phosphatidic Acid
- BMP Bis(Monoacylglycero)Phosphate
- MVB multivesicular bodies
- the invention further relates to products comprising a compound inducing LPBA accumulation in multi-vesicular bodies of a cell and an anti-HIV agent as combination products for simultaneous, sequential or separated use for the treatment and/or prevention of an infection with a HIV virus.
- HIV budding involves membrane curvature out of the cytoplasm, either within the endosomal lumen or into the extracellular medium. This process occurs physiologically in the cell by intraluminal vesicle budding into multivesicular bodies (MVB) and results in the internalisation and breakdown of membrane proteins, or the back-fusion to deliver the contents of the intraluminal vesicle into the cytoplasm, or the release of the exosome into the extracellular medium.
- MVB multivesicular bodies
- Lipid sorting is a key step in intracellular vesicle trafficking.
- LBPA(BMP) The lipid lysobisphosphatidic acid (LBPA(BMP)), also called BMP (bis(monoacylglycero)phosphate), is specifically located in the MVB and is necessary for endosome internal budding (Matsuo, Science. 2004;303:531-534).
- BMP bis(monoacylglycero)phosphate
- LBPA(BMP) interacts with Alix, an ESCRT-associated protein that also binds HIV.
- PFA2 MAFP- sensitive phospholipase A2
- MAFP methyl arachidonyl fluorophosphonate
- cPLA2 cytosolic calcium-dependent phospholipase A2
- PLA2 is also involved in the sorting of cholesterol between intracellular compartments and LBPA (BMP) is functionally associated with cholesterol and influences the cellular distribution of cholesterol.
- Cholesterol is essential for HIV biogenesis and infectivity.
- the lipid content of the virus envelope evokes that of lipid rafts and the depletion of cholesterol with methyl ⁇ -cyclodextrin reduces the infectivity of HIV.
- Cells can obtain free cholesterol by the internalization of LDL or by de novo synthesis.
- Another parameter of cellular lipid homeostasis is the intracellular distribution of cholesterol. High concentrations of progesterone retains cholesterol at the plasma membrane, so preventing its redistribution to intracellular membranes and, hence its esterification.
- the sterol analog, U18666A ⁇ -(2-Diethylaminoethoxy)androst-5-en-17-one, HCI), is also widely used to modify cholesterol synthesis and distribution, leading to cholesterol accumulation in the MVB compartment (Kobayashi, Nat Cell Biol. 1999;1 :1 13-1 18).
- U18666A inhibits two enzymes in the cholesterol biosynthesis pathway, squalene open cyclase and C8-C7 isomerase.
- the inventors have investigated the roles of cholesterol and PLA2 in HIV biogenesis, using U18666A and progesterone to modify the intracellular distribution and metabolism of cholesterol, and using the PLA2 inhibitor MAFP.
- the inventors evaluated the impact of these agents on the capacity of cells to support direct cell-to-cell HIV transfer.
- the inventors showed that progesterone and MAFP inhibit the egress of HIV, both involving the MVB compartment.
- Some viruses are known to bear a PLA2 activity.
- the human cytomegalovirus bears a host-cell derived PLA2 activity which is sensitive to inhibitors of cytosolic PLA2.
- Such inhibitors induce a decrease in de novo expression of certain viral proteins and of virus production (Allal, J. Virol. 2004;7717-7726).
- sequence analysis has revealed PLA2 motifs in capsid proteins of parvovirus. Mutations reducing PLA2 activity decrease viral infectivity. More precisely, this PLA2 activity is critical for efficient transfer of the viral genome into the nucleus to initiate replication (Zadori, Developmental Cell. 2001 ;291 - 302).
- Patent application EP 1 ,791 ,858 further describes the use of a modified VP1 -capsid protein of parvovirus B19 having a reduced PLA2 activity for use as a medicament for the treatment of a parvovirus infection.
- a PLA2 activity has ever been shown in the HIV replication cycle.
- Cholesterol biosynthesis has been shown to be important for the replication of norovirus. Indeed, the inhibition of cholesterol biosynthesis increases the level of norovirus proteins and RNA, whereas inhibitors of ACAT reduce the replication of norovirus (Chang, J. Virol. 2009;8587-8595). However, no effect of the inhibition of cholesterol biosynthesis has been shown on the HIV replication cycle.
- TNF synthesis in placental cells is induced by HIV-1 infection that, in an autocrine manner, activates viral replication, because neutralizing anti-TNF antibodies block it.
- Progesterone is believed to inhibit the induction of TNF synthesis by viral infection and virus or gp-120-induced TNF transcription. Such inhibition leads to a decrease in the production of HIV-1 RNA in placental cells at the concentration found in the placental interface (Munoz, JID 2007;1294-1302). However, no effect of progesterone has been shown on the late phase of the viral cycle.
- WO 2004/1 12724 teaches that progesterone is an inhibitor of HIV replication, and probably acts as a steroid hormone receptor antagonist that blocks the steroid hormone receptor complex that comprises Rip-1 .
- Rip-1 is a protein that binds to HIV Vpr and that has been shown to be partially responsible for mediating Vpr activity in the human host cell.
- WO 2004/1 12724 teaches the use of progesterone to therapeutically treat an individual infected with HIV in order to eliminate, reduce or stabilize viral titer and/or increase or stabilize CD4+ cell counts.
- WO 2004/1 12724 also teaches the use of progesterone to prevent a high risk individual from becoming infected with HIV.
- WO 2004/1 12724 does not teach that progesterone may interfere with cell to cell transmission of HIV.
- Cocaine is associated with an increased risk for, and progression of, clinical disease associated with human immunodeficiency virus (HIV) infection.
- HIV human immunodeficiency virus
- BD1047 a selective sigma-1 antagonist, can block the effects of cocaine on HIV replication in the huPBL-SCID mouse (Roth, J. Leukoc. Biol. 2005;78:1 198-203). More precisely, this blockage occurs before the viral transtion. However, no effect of this antagonist on the late phase of the viral cycle has been shown.
- the inventors have investigated the influence of cellular lipid homeostasis on the spread of HIV between monocyte-macrophage cells, a major component of the HIV reservoir. Altering cholesterol metabolism and distribution, or inhibiting the phospholipase A2 activity, led to an increase in the MVB-specific lysolipid lyso-bis phosphatidic acid (LBPA (BMP)) content and to the formation of large MVB.
- LBPA MVB-specific lysolipid lyso-bis phosphatidic acid
- PLA2 inhibitors and progesterone cause virus to become trapped inside intracellular vesicles, thus reducing the release of HIV to the cell periphery and increasing its intracellular storage (Example 3-6).
- PLA2 inhibitors and progesterone increase the LBPA (BMP) content in the MVB compartment (Example 8) and PLA2 inhibitors enhanced both the total number of MVB and their size (Example 7).
- progesterone and MAFP strongly inhibit HIV proliferation in THP-1 cells and in MDM, and greatly reduce the transfer of the HIV reservoir from MDM to PBL (Example 9-10).
- Progesterone is hypothesized to act via the Sigma-1 Receptor.
- Sigma-1 R is a receptor chaperone located in the smooth endoplasmic reticulum.
- Progesterone is an antagonist of this receptor (Maurice, Pharmacol Ther. 2009;124:195-206), while cocain, which enhances HIV production, is an agonist.
- PLA2 is involved downstream of the Sigma-1 Rs, and blocking these receptors with progesterone could, at least partly, inhibit PLA2 and so increase the cell LBPA (BMP) content ( Figure 7).
- Sigma-1 Rs could regulate the "cross-talk" between cholesterol, progesterone, and PLA2, and account for the effects described by the inventors.
- LBPA human monocyte-derived macrophages
- LPBA Lyso-Bis Phosphatidic Acid
- MAFP multi-vesicular bodies
- the present invention pertains to a compound inducing Lyso-Bis Phosphatidic Acid (LPBA) accumulation in multi-vesicular bodies (MVB) of a cell for use for inhibiting i) cell-to-cell transmission of a Human Immunodeficiency Virus (HIV), and/or ii) entry of HIV into a cell (more particularly entry which involves endocytosis, preferably which involves macropinocytosis), in an individual in need thereof.
- LPBA Lyso-Bis Phosphatidic Acid
- the present invention also relates to a method for inhibiting i) cell-to-cell transmission of a Human Immunodeficiency Virus (HIV), and/or ii) entry of HIV into a cell (more particularly entry which involves endocytosis, preferably which involves macropinocytosis), said method comprises a step wherein an individual in need thereof is administered with an effective amount of a compound inducing Lyso-Bis Phosphatidic Acid (LPBA) accumulation in multi-vesicular bodies (MVB) of a cell.
- LPBA Lyso-Bis Phosphatidic Acid
- Endocytosis is a process by which cells absorb molecules (such as virus) by engulfing them.
- the term “macropinocytosis” is intended to mean a biological mechanism which involves the invagination of the cell membrane to form a pocket comprising the virus, said pochet then pinches off into the cell to form a vesicle. The vesicle then travels into the cytosol and fuses with other vesicles such as endosomes and lysosomes. The formation of the pocket occurs in a non-specific manner, then does not need any specific receptor.
- HIV Human Immunodeficiency Virus
- M any group
- N O or P
- HIV is HIV-1 .
- the newly synthesized virions are directly transmitted from an infected cell to another cell without between released in the extracellular compartment.
- the compound of the invention is intended for use for inhibiting direct or indirect cell- to-cell transmission.
- the compound of the invention is intended for use for inhibiting direct cell-to-cell transmission.
- HIV budding involves membrane curvature out of the cytoplasm, either within the endosomal lumen or into the extracellular medium. This process occurs physiologically in the cell by intraluminal vesicle budding into multi-vesicular bodies (MVB).
- MVBs also known as late endosomes, are mainly spherical, lack tubules, and contain many close- packed luminal vesicles. Markers include RAB7 and RAB9 and mannose 6-phosphate receptors. The inventors have shown that inhibiting the phospholipase A2 activity leads to the formation of large MVB.
- the Lyso-Bis Phosphatidic Acid (LBPA (BMP)
- BMP Bis Mono-acyl-glycero Phosphate
- LBPA (BMP) accumulation in multi-vesicular bodies (MVB) may be measured by various methods well-known by one skilled in the art. For instance, it may be quantified by intracellular MVB LBPA (BMP) immuno-labeling using for instance the 6C4 anti-LBPA (BMP) antibody and microscopy or FACS analysis, as described in Example 8. Alternatively, LBPA (BMP) may be separated by two-dimensional thin-layer chromatography followed by an HPLC isolation on Nucleosil-NH2 support and biochemical quantification of its fatty acid content may be performed by gas chromatography.
- an increase in the LBPA (BMP) content in the MVB compartment of at least 10%, 20%, 30%, 40% or 50% in cells treated with the compound compared to untreated cells is indicative of a LBPA (BMP) accumulation in the MVB.
- the compound inducing Lyso-Bis Phosphatidic Acid (LPBA) accumulation in multi-vesicular bodies (MVB) of a cell for use for inhibiting cell-to-cell transmission of a HIV in an individual in need thereof is a Phospholipase A2 (PLA2) inhibitor or a Sigma-1 Receptor antagonist.
- PLA2 inhibitor is meant a compound that inhibits the activity and/or the expression of the Phospholipase A2.
- Sigma-1 Receptor antagonist is meant a compound that inhibits the activity and/or the expression of the Sigma-1 Receptor.
- the inhibitors or antagonists according to the invention are direct inhibitors or antagonists that bind to their targets.
- the compound inducing LBPA (BMP) accumulation may be a small molecule, an organic or inorganic compound, a peptide inhibitor, a peptidomimetic, an antibody, a lipid, an antisense, an RNA interference, an aptamer, or a ribozyme blocking PLA2 or Sigma- 1 R activity and/or expression.
- said compound is selected from the group consisting of MAFP (methyl arachidonyl fluorophosphonate), ATMK / AACOCF3 (arachidonyl trifluoromethyl ketone), Pyrrolidine-2 (N- ⁇ (2S,4R)-4-(Biphenyl-2-ylmethyl-isobutyl-amino)- 1 -[2-(2,4-difluorobenzoyl)-benzoyl]-pyrrolidin-2-ylmethyl ⁇ -3-[4-(2,4-dioxothiazolidin-5- ylidenemethyl)-phenyl]acrylamide, HCI), Pyrrophenone (N-[[(2S,4R)-1 -[2-(2,4- difluorobenzoyl)benzoyl]-4-[(triphenylmethyl)thio]-2-pyrrolidinyl]methyl]-4-[(Z)-(2,4-dioxo-5- thiazolidin
- the compound inducing LPBA accumulation in multi-vesicular bodies (MVB) is not progesterone.
- Interfering with cell to cell transmission of HIV prevents viral load from increasing. It may also result in a decrease of viral load if the cells infected with HIV are eliminated by the immune system or if an anti-HIV is used in combination with the compound inducing LPBA accumulation in multi-vesicular bodies (MVB).
- MVB multi-vesicular bodies
- the invention also pertains to a compound inducing Lyso-Bis Phosphatidic Acid (LPBA) accumulation in multi-vesicular bodies (MVB) for use for decreasing the viral load of a patient infected with HIV.
- LPBA Lyso-Bis Phosphatidic Acid
- MVB multi-vesicular bodies
- viral load refers to the amount of virus present in an involved body fluid. For example, it can be given in RNA copies per milliliter of blood plasma. Different techniques for measuring the viral load are well-known by the one skilled in the art. These include PCR, RT-PCR, ELISA and/or determination of virus-associated reverse transcriptase (RT) activity.
- the compound inducing LPBA accumulation in multi-vesicular bodies include PCR, RT-PCR, ELISA and/or determination of virus-associated reverse transcriptase (RT) activity.
- the compound inducing LPBA accumulation in multi-vesicular bodies include PCR, RT-PCR, EL
- the expression "individual in need thereof” is intended for a human or non-human mammal infected or likely to be infected with HIV.
- the patient is a human.
- the individual in need of a compound inducing Lyso-Bis Phosphatidic Acid (LPBA) accumulation in multi-vesicular bodies (MVB) of a cell for use for inhibiting cell-to- cell transmission of a HIV is a symptomatic individual suffering from a HIV infection.
- LPBA Lyso-Bis Phosphatidic Acid
- HIV infection refers to the condition of an individual who is infected with HIV. HIV infection indifferently denotes an asymptomatic HIV infection or a symptomatic HIV infection including the acquired immunodeficiency syndrome (AIDS), whatever its stage of development. Therefore, according to some embodiment, the individual is a symptomatic individual suffering from AIDS. In another embodiment, the individual is an asymptomatic individual who has been exposed or is at risk of having been exposed to HIV. Such individuals include health care or other individuals who may have accidentally exchanged blood or other biological fluids with an HIV-infected individual, such as through an accidental needle stick, injuries that occur during emergency medical care, rescue or arrest and unprotected sexual contact. Additionally, the present invention is particularly useful to prevent recurrence of infection in patients who have been previously diagnosed as HIV positive but show no indication of infection.
- HIV virus may infect different types of cell including monocytes, macrophages, and lymphocytes. Therefore, in a preferred embodiment the cell wherein the compound of the invention is intended to induce LPBA accumulation in MVB is a monocyte, a macrophage or a lymphocyte. More preferably, the cell is a T lymphocyte. Even more preferably, the cell is a T helper lymphocyte (LT4).
- LT4 T helper lymphocyte
- inhibiting cell to cell transmission of HIV means inhibiting HIV transmission from a monocyte to a monocyte and/or to a macrophage and/or to a lymphocyte. Inhibiting cell to cell transmission of HIV can also mean inhibiting HIV transmission from a macrophage to a monocyte and/or to a macrophage and/or to a lymphocyte. Alternatively, inhibiting cell to cell transmission of HIV can also mean inhibiting HIV transmission from a lymphocyte to a monocyte and/or to a macrophage and/or to a lymphocyte.
- the compound of the invention is preferably for use for inhibiting cell-to-cell transmission of HIV from a monocyte, or a macrophage, or a lymphocyte to a lymphocyte.
- the compound of the present invention may be administered as a pharmaceutical composition.
- another aspect of the invention pertains to a pharmaceutical composition comprising a compound inducing LPBA accumulation in multi-vesicular bodies of a cell for the treatment and/or prevention of HIV infection.
- the term "treatment” means the action of reversing, alleviating, inhibiting the progress of the HIV infection, or one or more symptoms of such infection.
- the present combination products may be used for preventing HIV infection in high risk individuals who, for example, are suspected of having been exposed to the virus.
- Pharmaceutical compositions comprising a compound of the invention include all compositions wherein the peptide is contained in an amount effective to achieve the intended purpose.
- the pharmaceutical compositions may contain suitable physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
- physiologically acceptable carrier is meant to encompass any carrier, which does not interfere with the effectiveness of the biological activity of the active ingredient and that is not toxic to the host to which is administered. Suitable physiologically acceptable carriers are well known in the art and are described for example in Remington's Pharmaceutical Sciences (Mack Publishing Company, Easton, USA, 1985)., which is a standard reference text in this field.
- the above active ingredients may be formulated in unit dosage form for injection in vehicles such as saline, dextrose solution, serum albumin and Ringer's solution.
- compositions of the invention can also comprise minor amounts of additives, such as stabilizers, excipients, buffers and preservatives.
- composition of the invention may further comprise a second active principle, in particular an anti-HIV therapeutic agent.
- a second active principle in particular an anti-HIV therapeutic agent.
- the compound of the invention and the anti-HIV therapeutic agent may have a complementary action.
- the compound of the present invention may be administered either as an individual therapeutic agent or in combination with other therapeutic agents, in particular anti-HIV therapeutic agents.
- another aspect of the invention pertains to products comprising a compound inducing LPBA accumulation in multi-vesicular bodies of a cell and an anti- HIV agent as combination products for the treatment and/or prevention of HIV infection.
- the combination products comprising the compound of the invention and an anti- HIV agent may be formulated as separate pharmaceutical compositions and may be administered sequentially or simultaneously or used separated.
- An "anti-HIV agent” denotes a compound which leads to decreased HIV replication.
- Integrase inhibitors inhibit the enzyme integrase, which is responsible for integration of viral DNA into the DNA of the infected cell.
- Examples of integrase inhibitors include raltegravir and elvitegravir which is currently under clinical trial.
- Reverse transcriptase inhibitors include nucleoside and nucleotide reverse transcriptase inhibitors (NRTI) and non-nucleoside reverse transcriptase inhibitors (NNRTI).
- NRTI nucleoside and nucleotide reverse transcriptase inhibitors
- NRTI non-nucleoside reverse transcriptase inhibitors
- NRTI inhibit reverse transcription by being incorporated into the newly synthesized viral DNA and preventing its further elongation.
- Abacavir (ABC)
- emtricitabine FTC
- didanosine (ddl)
- lamivudine (3TC)
- stavudine (d4T)
- zidovudine (AZT)
- tenofovir TDF
- NNRTI inhibit reverse transcriptase directly by binding to the enzyme and interfering with its function.
- Delavirdine, efavirenz (EFV), nevirapine (NVP), etravirine (ETV) are four currently available agents in this class.
- Protease inhibitors target viral assembly by inhibiting the activity of protease, an enzyme used by HIV to cleave nascent proteins for final assembly of new virions.
- protease inhibitors include atazanavir, darunavir, indinavir, fosamprenavir, lopinavir, nelfinavir, saquinavir, tripanavir and ritonavir.
- Entry inhibitors include fusion inhibitors and CCR5 inhibitors. They interfere with binding, fusion and entry of HIV-1 to the host cell by blocking one of several targets. Maraviroc and vicriviroc (which is currently under clinical trial) are CCR5 inhibitors and enfuvirtide is one currently available fusion inhibitor. Maturation inhibitors inhibit the last step in gag processing in which the viral capsid polyprotein is cleaved, thereby blocking the conversion of the polyprotein into the mature capsid protein. Because these viral particles have a defective core, the virions released consist mainly of non-infectious particles. Two drugs in this class are under investigation, bevirimat and Vivecon.
- the invention also pertains to products comprising a compound inducing LPBA accumulation in multi-vesicular bodies of a cell and an anti-HIV agent selected from the group consisting of integrase inhibitors, reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, fusion inhibitors, CCR5 inhibitors, and maturation inhibitors as combination products for simultaneous, sequential or separated use for the treatment and/or prevention of an infection with a HIV virus.
- an anti-HIV agent selected from the group consisting of integrase inhibitors, reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, fusion inhibitors, CCR5 inhibitors, and maturation inhibitors
- the invention pertains to a pharmaceutical composition
- a pharmaceutical composition comprising a compound inducing LPBA accumulation in multi-vesicular bodies of a cell and an anti-HIV agent selected from the group consisting of integrase inhibitors, reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, fusion inhibitors, CCR5 inhibitors, and maturation inhibitors.
- an anti-HIV agent selected from the group consisting of integrase inhibitors, reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, fusion inhibitors, CCR5 inhibitors, and maturation inhibitors.
- the compound of the present invention may be administered by any means that achieve the intended purpose.
- administration may be achieved by a number of different routes including, but not limited to subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intracerebral, intrathecal, intranasal, oral, rectal, transdermal, buccal, topical, local, inhalant or subcutaneous use. Parenteral and topical routes are particularly preferred.
- Dosages to be administered depend on individual needs, on the desired effect and the chosen route of administration. It is understood that the dosage administered will be dependent upon the age, sex, health, and weight of the recipient, concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
- the total dose required for each treatment may be administered by multiple doses or in a single dose.
- the compounds are provided over a course of time in which a therapeutically effective amount of compound is present in the individual's body so as to reduce the viral load to essentially undetectable levels or essentially undetectable levels such that an asymptomatic individual will not develop symptoms or the onset of such symptoms shall be delayed.
- the compounds may be formulated as liquid (e.g., solutions, suspensions), solid (e.g., pills, tablets, suppositories) or semisolid (e.g., creams, gels) forms.
- liquid e.g., solutions, suspensions
- solid e.g., pills, tablets, suppositories
- semisolid e.g., creams, gels
- an effective amount is meant an amount sufficient to achieve a concentration of compound which is capable of preventing, treating or slowing down the disease to be treated. Such concentrations can be routinely determined by those of skilled in the art.
- the amount of the compound actually administered will typically be determined by a physician or a veterinarian, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the subject, the severity of the subject's symptoms, and the like. It will also be appreciated by those of skilled in the art that the dosage may be dependent on the stability of the administered compound.
- FIGURES Figure 1 Effect of U18666A and progesterone on HIV infection of THP1 cells.
- Data are expressed as HIV RNA log 10 copies / million viable cells.
- Infected and uninfected THP-1 cells were mixed in a 1 :1000 ratio and drugs added to the culture each day.
- the final concentration on day 4 was 20 ⁇ for MAFP, 40 ⁇ for progesterone (PROG), 28 ⁇ for U18666A (U18), 20 ⁇ for zidovudine (AZT) and 40 ⁇ for lopinavir (LPV).
- HIV-1 RNA in the culture supernatant was quantified as HIV-1 RNA Iog10 copies / million viable cells.
- the graph represents the mean of 8 independent experiments and the bars the standard error of the mean. Differences between each drug and the control are significant (p ⁇ 0.05).
- Monocytes-derived macrophages were prepared as described in "Material and Methods", infected by coculture (ratio 1 :100) and treated by repeated additions of the three drugs to reach final concentrations at day 4 of 15 ⁇ for MAFP, 30 ⁇ for progesterone, 21 ⁇ for U18666A.
- the HIV-1 RNA in the culture medium was normalized to the signal (relative luminescence units) obtained for viable cells with the Cell Titer Glo ® Promega kit and expressed relative to the control.
- the graph represents the mean of 5 independent experiments and the bars the standard error of the mean. Differences are significant between MAFP, PROG, U18 and the control (p ⁇ 0.05).
- FIG. 4 Effect of methyl arachidonyl fluorophosphonate (MAFP), a cytosolic phospholipase A2 inhibitor, on HIV production by THP1 cells.
- MAFP methyl arachidonyl fluorophosphonate
- Data are expressed as HIV RNA log 10 copies / million viable cells.
- the integrity of the overall MVB compartment was evaluated, qualitatively by immunofluorescence, and quantitatively by FACS by incubating cells with Rh-PE, a fluorescent lipid that specifically targets the MVBs. Immunofluorescence was examined with a Zeiss wide-field microscope (objective lens 63X) Bar 10 ⁇ . Cells were examined on day 4.
- Cells at low infection ratio (1 :1000) were cultured for 4 days in the presence of daily additions of ethanol (vehicle), MAFP (5 ⁇ ), or progesterone (10 ⁇ ). After 4 days of coculture, i.e on cells in presence of 20 ⁇ MAFP or 40 ⁇ progesterone. Cells were then immunolabeled with anti-LBPA (BMP) antibody and the fluorescent signal quantified on a BD FACS Calibur. Each symbol represents an independent experiment. Data are expressed as mean fluorescence intensity (MFI) (Expt 4 O, Expt 5 O, Expt 6 ⁇ ).
- MFI mean fluorescence intensity
- FIG. 1 Effect of progesterone and PLA2 inhibitor MAFP on HIV production by cell-to-cell infection of human MDM.
- MDM were prepared as described in Example 1 , infected by coculture (ratio 1 :100) and treated by repeated additions (every two days) of 10 ⁇ progesterone, 5 ⁇ MAFP or 5 ⁇ AZT. HIV RNA was measured on day 4 of treatment (i.e at final concentrations of 15 ⁇ of MAFP or AZT and 30 ⁇ progesterone). HIV RNA was normalized to the signal obtained from viable cells with the Cell Titer Glo ® Promega kit. p ⁇ 0.005 for MAFP, progesterone or AZT, versus control.
- Figure 9 Effect of MAFP and progesterone on direct cell-to-cell transfer.
- a PCR experiment was performed on HIV DNA extracts from unadherent autologous leukocytes cocultivated with MDM, following repeated additions (every two days) of ethanol (CTL), MAFP 5 ⁇ or 10 ⁇ progesterone and 10 ⁇ lopinavir. Quantification of the effect of MAFP and progesterone is expressed as the 2 [ delta(deltaCt)l count for a single addition on day 0 (Expts 1 and 2), or for repeated additions (Expts 3-5, p ⁇ 0.0001) of MAFP or progesterone, versus control.
- THP-1 cells were treated each day to obtain final concentrations on day 4 of 20 ⁇ for MAFP, 40 ⁇ for progesterone (PROG) and 28 ⁇ for U18666A (U18). Endocytosis was monitored by the internalization of FITC dextran. Histograms represent the fluorescence measured at 4°C (dashed lines) and at 37°C (solid lines). Similar results were obtained in three independent experiments.
- Infected and uninfected THP-1 cells were mixed in a 1 :1000 ratio and drugs added to the culture each day.
- the final concentration on day 4 was 20 ⁇ for MAFP, 40 ⁇ for progesterone (PROG) and 28 ⁇ for U18666A (U18).
- the cells were labeled with anti- CD4, anti-CCR5, anti-CXCR4, anti-LFA-1 and anti- ICAM-1 antibodies and analysed using a BD Biosciences LSRII Flow CytometerTM.
- the Mean Fluorescence Intensity (MFI) was calculated using the DIVATM software.
- the graph represents the mean of 3 independent experiments and the bars the standard error of the mean.
- Infected and uninfected THP-1 cells were mixed in a 1 :1000 ratio and drugs added each day to obtain the final concentrations of MAFP, progesterone (PROG) and U18666A (U18) on day 4.
- the cells were stained with the 6C4 anti-LBPA (BMP) antibody and analysed by FACS.
- A BMP quantified by the mean fluorescence intensity (MFI) of the cell population and expressed as percentage of that of the controls.
- B Representative FACS profiles for each drug. The percentage of labeled cells and the MFI are shown.
- SEQ ID NO: 1 shows the sequence of a forward primer specific for the gag-LTR sequence
- SEQ ID NO: 2 shows the sequence of a reverse primer specific for the gag-LTR sequence
- SEQ ID NO: 3 shows the sequence of a Taqman® probe
- SEQ ID NO: 4 shows the sequence of a forward primer specific for the beta-actin gene
- SEQ ID NO: 5 shows the sequence of a reverse primer specific for the beta-actin gene
- Rhodamine-PE [(1 ,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N- (lissamine rhodamine B sulfonyl)] was purchased from Avanti Polar Lipids, Birmingham, Alabama, USA. Progesterone and filipin were supplied by Sigma-Aldrich Chimie S.a.r.l. Lyon, France. MAFP was obtained from Biomol International (Enzo Life Sciences, Villeurbanne, France). Macrophage colony stimulating factor (M-CSF) was purchased from Miltenyi Biotec SAS, Paris, France. QIAamp Viral mini kits and QIAamp DNA blood mini kits were purchased from Qiagen SA, Courtaboeuf, France.
- RT-PCR kits were from Roche Diagnostics, Meylan, France. Culture media and FITC-dextran (MW 10,000) were supplied by Invitrogen SARL, Cergy Pontoise, France. Lopinavir (LPV) and zidovudine (AZT) were obtained from the NIH Research Reagents Program, Germantown, MD, USA. U18666A ⁇ -(2-Diethylaminoethoxy)androst-5-en-17-one, HCI) was purchased from Sigma. PE-labeled goat anti-mouse IgG antibody was from AbD Serotec, Colmar, France.
- Anti-LBPA (BMP) antibody was a generous gift from T Kobayashi (Lipid Biology Laboratory, RIKEN Institute, Saitama, Japan).
- PE-anti-CD206, Pacific blue anti-CD4, APC-anti-CD54 (ICAM-1 ), FITC anti-CD1 1 a (LFA-1 ), PE- anti-184 (CXCR4) and PerCP- Cy5.5 anti-CD195 (CCR5) and compensation beads were obtained from BD biosciences, Le Pont de Claix, France.
- anti-HIV-1 (KC-57 FITC) from Beckman Coulter, Fullerton, USA.
- the human promonocytic THP-1 cells were purchased from the ATCC (ATCC number TIB-202TM) and maintained at 5.10 5 cells/ml in RPMI 1640 supplemented with 10 % heat-inactivated fetal calf serum (10% FCS RPMI).
- Peripheral blood mononuclear cells were prepared from buffy coats from healthy donors (Etabl ordinance frangais du sang, Toulouse), plated in 6-well plates (10 7 cells/well) and incubated for 2 hours at 37°C.
- Adherent monocytes were washed three times with phosphate-buffered saline (PBS) and cultured for 7 days in RPMI -10% FCS containing 25 ng/ml M-CSF to trigger their differentiation into macrophages (MDM, monocyte-derived macrophages). The differentiation from monocytes to macrophages was monitored by quantifying CD206 by FACS.
- THP-1 cells The viability of THP-1 cells was analysed by trypan blue staining and that of MDM using the luminescent assay, Cell Titer Glo kit ® (Promega). Infection
- THP-1 cells were infected with the HIV LA
- THP-1 cells infected as described above on day 0 collected by centrifugation, and mixed with uninfected THP-1 at various ratios.
- infected MDM were scraped off the plate, collected, and added to uninfected MDM in a ratio of 1 :100.
- THP1-cells Treatment of THP1-cells on day 0. Molecules were added to the culture medium containing 1 % FCS of mixed infected and uninfected cells on day 0 to give the indicated final concentration.
- MDM were infected with the HIV Ba -i_ strain as described above. Treatment was repeated every two days. Lopinavir (10 ⁇ ) was added on day 6, and treatment continued for 4 more days. The cells were washed on day 10 incubated with autologous PBL for three hours for contact with MDM containing potentially infectious virus stores. Nonadherent cells were then cultivated for two days in RPMI 10% FCS and their infection evaluated by measuring their HIV DNA content.
- DNA was extracted from 10 6 cells using QIAamp DNA blood mini kits (Qiagen) and quantified by real time PCR targeting a gag-LTR sequence using the following primers, forward 5'-GCCTCAATAAAGCTTGCCTTGA (SEQ ID NO: 1 ) and reverse 5'- GCTCTCTCGACGCAGGACT (SEQ ID NO: 2), and detected with the Taqman® probe 5'- 6Fam-AAGTAGTGTGTGCCCGTCTGTTRTKTGACT-Tamra-3' (SEQ ID NO: 3). Each run was for 45 cycles.
- the beta-actin gene in each sample was amplified using the primers: forward 5 ' -G ATG AG ATTG G C ATG G CTTT (SEQ ID NO: 4) and reverse 5'- AGAGAAGTGGGGTGGCTTTT (SEQ ID NO: 5), and the products were detected using SyBRgreen®.
- the HIV/beta-actin DNA ratio was evaluated using the 2 [ delta(deltaCt)l count.
- Rh-PE labeling Appropriate amounts of Rh-PE stored in in chloroform:methanol (2:1 ) were dried and suspended in absolute ethanol. The ethanolic solutions were diluted with PBS to give the final concentration (3 ⁇ ) and vortexed vigorously. An aliquot (1 ml) of this mixture was then added to 2.10 6 cells per condition. These cells had been treated for 4 days and collected by centrifugation. The cells were incubated with Rh-PE for 60 min at 4 ⁇ . The medium was then removed, the cells extensively washed with PBS containing 3% w/v BSA, and they were incubated in 1 % FCS RPMI for 3 hours at 37°C. A sample of 3.10 5 labeled cells was washed in PBS and fixed with PFA 3.7% for 20 min.
- FACS analysis labeled cells were analysed using a BD Biosciences FACSCalibur
- Lyso bis phosphatidic acid (LBPA (BMP), or bis(monoacylglycero)phosphate [BMP]) quantification
- the cells were washed again and incubated with PE- conjugated goat anti-mouse antibodies for 45 min at 4°C. Finally, they were washed and analysed in a BD Biosciences FACSCalibur Flow CytometerTM and WinMDITM software.
- Biochemical quantification of LBPA (BMP): Lipids were extracted from 50.10 6 cells with chloroform and methanol plus the antioxidant bromohydroxytoluene (BHT). Internal standard (C 15 BMP) was added and LBPA (BMP) was measured by chromatography.
- Macropinocytosis of THP-1 cells was measured by their uptake of FITC-dextran.
- Cells (5.105) were incubated with 1 mg/ml FITC-dextran in PBS with 2% FCS for 30 min either at 4°C to block endocytosis and to measure nonspecific binding, or at 37 ⁇ to measure specific uptake. The cells were then washed three times in cold PBS-FCS and analysed using a BD Biosciences FACSCalibur Flow CytometerTM and FlowJoTM software.
- Ultrathin sections (70 nm thick) were cut and mounted on 150 mesh collodion-coated copper grids and poststained with 3% uranyl acetate in 50% ethanol and with 8.5% lead citrate.
- the embedded cells were examined in a HU12A Hitachi electron microscope at an accelerating voltage of 75 KV.
- Graphs were prepared with GraphPad Prism software and statistical analyses were done using StatView software (SAS Institute Inc), including the F-test for comparing variances and Student's f-test for comparing results.
- Example 2 HIV infection between monocytic THP1 cells
- Infected monocytic THP1 cells were mixed with uninfected ones in various ratios, and the amounts of virus released from the cells over time was measured. The ratios between cells varied from 1 infected cell to 2 uninfected ones ("high infection ratio”), to 1 infected cell to 1000 uninfected ones ("low infection ratio”) and reached a plateau on day 4 in all the conditions tested. Cell proliferation was at a steady-state.
- a very high titer (10 9 HIV RNA copies / ml culture medium) was obtained with a ratio of 1 :2 and infected cells had to be diluted 1000-fold to obtain a virus titer of 10 6 RNA copies / ml.
- the virus titer on day 4 was correlated with the ratio of infected to uninfected cells. Therefore, imaging analyses and LBPA (BMP) measurements were performed on day 4.
- AZT inhibited the infection by 1 log even at a high infection ratio (1 :2), which is consistent with its effect in vitro.
- Intracellular trafficking requires constant changes in the lipid composition of membranes and cholesterol is critical because any impairment of its distribution leads to cellular defects. HIV itself modulates the host cell cholesterol content. The inventors therefore investigated the influence of the cellular cholesterol distribution on HIV production under the experimental conditions outlined in Example 2.
- U18666A a cationic amphiphilic compound causes the cholesterol precursors desmosterol and squalene epoxyde to accumulate in endosomes.
- U18666A had a small, transient effect on day 2 which no longer persisted for longer periods (Figure 1A) even when the ratio of infected /uninfected cells was low ( Figure 1 A1 ), or when repeated amounts of U18666A were added.
- Progesterone causes cholesterol to accumulate at the cell periphery, a different distribution to that caused by U18666A.
- Progesterone (10 ⁇ ) added on day 0 inhibited HIV production by one log by THP1 cells in a low ratio of infected/un infected cells (1 :1000) ( Figure 1 B), and by about 0.5 log at a high ratio (1 :2) of infected/un infected cells ( Figure 1 B2).
- Adding progesterone each day to a high ratio (1 :2) of infected/un infected cells was no more effective than a single addition at day 0.
- the inventors used filipin staining to monitor the distribution of free sterols in infected cells. There was no apparent difference between infected and uninfected cells. The cholesterol in cells cultured at an infected/un infected cells ratio of 1 :1000 was diffusely distributed through the cytoplasm. U18666A increased the accumulation of free cholesterol and its precursors in the intracellular vesicles of these cells, while progesterone caused free cholesterol to accumulate at the cell periphery. Similar results were obtained when cells were cultured at an infected/un infected cell ratio of 1 :2.
- Electron microscope examination of cells cultured with U18666A for four days showed that the virus was mainly around the cells, while cells cultured with progesterone showed no accumulation of virus around the cell, but HIV was inside intracellular vesicles. Therefore, the redistribution of cellular cholesterol appears to play a key role in the control of virus release.
- Example 4 Influence of MAFP and progesterone on HIV-1 release from THP-1 cells and on HIV-1 intracellular stores
- HIV release in the supernatant of cocultures of HIV-infected and non infected THP-1 cells depends on the ratio of these infected to non infected cells, (data not shown).
- concentrations given preliminary results in the laboratory. Cultures were treated from day 0 to 3 with selected drugs and analyzed at day 4. The cytotoxicity observed after cell staining was not higher for MAFP and progesterone than for antiretroviral treatments already used in HAART, especially lopinavir, and was similar in non infected cultures and in cocultures of infected and uninfected cells mixed in a ratio of 1 :1000 ( Figure 2A).
- the ATP content of viable cells was quantified as a control of their global metabolic activity, which was in the same range whatever the treatment was ( Figure 2B), and was similar between infected and uninfected cells.
- HIV-1 release was measured in the culture supernatant by quantification of HIV-1 RNA relatively to the number of viable cells.
- MAFP and progesterone induced a significant decrease in the HIV-1 released into the culture supernatant on day 4, the virus titer being 0.5 to 0.75 log 10 lower than that of the control (Figure 2C).
- Example 5 Influence of MAFP and progesterone on HIV-1 release from primary cultures of human monocyte-derived macrophages (MDM)
- MAFP and progesterone were confirmed. Compared to control and whatever the treatment was, around 75 % of cells were viable at day 4 of coculture of infected and non infected cells ( Figure 3A, left bars). MAFP and progesterone strongly inhibited HIV-1 infection of MDM. Compared to control, 15% and 10% of HIV-1 RNA were retrieved in the cell supernatant for MAFP and progesterone respectively ( Figure 3A, right bars). Also, confocal microscopy experiments showed that this decrease of HIV-1 release was associated to the accumulation of BMP in treated cells (data not shown). Like in THP-1 cells, control MDM cells were faintly stained by the anti-BMP antibody, whereas the treated ones had accumulated BMP in intracellular vesicles.
- Example 6 Effect of a cPLA2 inhibitor on HIV infection of THP1 cells
- PLA2 activity regulates cholesterol-induced Golgi vesiculation and its lipolytic activity enables the cell to generate outward-bending membranes and to regulate membrane trafficking events.
- the inventors therefore examined the influence of PLA2 inhibition on HIV production by determining the effect of the PLA2 inhibitor, methyl arachidonyl fluoro phosphonate (MAFP) on the spread of HIV in cell cultures.
- MAFP methyl arachidonyl fluoro phosphonate
- MAFP methyl arachidonyl fluoro phosphonate
- Example 7 Effect of the lipid molecules on the MVB compartment of THP1 cells
- Rh-PE labeling As treatment with progesterone or MAFP caused the virus to accumulate in the large intracellular compartments, the inventors examined the influence of these molecules on the MVB compartment using Rh-PE labeling.
- the fluorescent probe Rh-PE accumulates specifically in the MVB compartment when it is added to cells.
- the Rh-PE in MVBs was quantified by FACS, so providing an estimation of the total volume of the MVBs in cells.
- immunofluorescence microscopy of Rh-PE labeled cells was used to monitor the morphology of MVBs ( Figure 5).
- MAFP enhanced both the total number of MVB (Figure 5F) and their size (Figure 5E), which can act as a storage compartment for HIV, as the virus is no longer released from the cell.
- Figure 5D the MVB compartment in infected progesterone-treated cells was not modified ( Figure 5D), the effect of progesterone on HIV was similar to that of MAFP; they both reduced the release of HIV to the cell periphery and increased its intracellular storage ( Figures 1 and 4).
- Example 8 LBPA (BMP) (BMP) content
- a change in the MVB content of cells should also lead to changes in the amount of LBPA (BMP) that accumulates in MVB.
- BMP LBPA
- the inventors used two experimental methods to quantify cellular LBPA (BMP). One was lipid extraction and chromatography and the other was FACS analysis of cells incubated with an anti-LBPA (BMP) antibody ( Figures 6-7). Although there was great inter-experimental variability, both methods showed similar results ( Figures 6-7). MAFP increased the LBPA (BMP) content 1 .5-fold to 7-fold, while progesterone produced an even greater increase in the LBPA (BMP) in the MVB compartment, 3-fold to 10-fold ( Figure 7). While the increase in LBPA (BMP) produced by progesterone involved the whole cell population, MAFP acted on a subpopulation of cells.
- the inventors checked the effects of progesterone and MAFP observed on THP1 cells by repeating the tests on human monocyte-derived macrophages and comparing the responses to that of AZT-treated cells (Figure 8).
- the test compounds were added to the cells every two days (repeated treatment) because MAFP has more effect under these conditions ( Figure 4C).
- Progesterone and MAFP both strongly inhibited HIV proliferation in MDM, as they did in THP-1 cells ( Figure 8).
- Example 10 Effect of progesterone and PLA2 inhibition on direct HIV cell-to- cell transfer
- MAFP and progesterone increase the LBPA (BMP) content of cells, leading to the sequestration of HIV in large intracellular stores that have many of the features of MVB. This is associated with decreased HIV secretion. This retention of HIV in cells prompted us to examine the effects of MAFP and progesterone on the direct transfer of HIV from one cell to another.
- the inventors first cultured the MDM for six days to ensure that the cells were filled with mature virus particles. The intracellular stores of virus constituted in these first days after infection remain infectious for several weeks. The production of new infectious virus particles was then blocked by incubating the cells with the protease inhibitor lopinavir for four days. These MDM were then cultured with autologous non-adherent leukocytes for three hours at day 10.
- Endocytosis is involved in HIV entry and components of late endosomes are recruited for HIV budding (Benaroch et al., Retrovirology, 7: 29, 2010).
- the inventors investigatd whether HIV trapping into intracellular compartments upon MAFP or progesterone treatment could result of their effect at some steps of the endocytosis pathway.
- the inventors monitored endocytosis using FITC-dextran. After uptake, dextrans move through the endocytic track up to the lysosomes and thus, they are good tracers of membrane-impermeable cargo along the endocytic track.
- Example 12 Influence of MAFP and progesterone on the BMP content and sterol distribution inTHP-1 cells
- MAFP and progesterone inhibit the macropinocytosis. This inhibition might occur by modification of raft formation in the plasma membrane as reported for high concentration of progesterone.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention concerns a compound inducing Lyso-Bis Phosphatidic Acid (LPBA) accumulation in multi-vesicular bodies (MVB) of a cell for use for inhibiting i) cell-to-cell transmission of a Human Immunodeficiency Virus (HIV), and/or ii) entry of HIV into a cell, in an individual in need thereof. The invention further relates to products comprising a compound inducing LPBA accumulation in multi-vesicular bodies of a cell and an anti-HIV agent as combination products for simultaneous, sequential or separated use for the treatment and/or prevention of an infection with a HIV virus.
Description
COMPOUND INDUCING LBPA ACCUMULATION FOR INHIBITING CELL-TO-CELL TRANSMISSION OF HIV
The present invention concerns a compound inducing Lyso-Bis Phosphatidic Acid (LBPA), also named Bis(Monoacylglycero)Phosphate (BMP), accumulation in multivesicular bodies (MVB) of a cell for use for inhibiting i) cell-to-cell transmission of a Human Immunodeficiency Virus (HIV), and/or ii) entry of HIV into a cell, in an individual in need thereof. The invention further relates to products comprising a compound inducing LPBA accumulation in multi-vesicular bodies of a cell and an anti-HIV agent as combination products for simultaneous, sequential or separated use for the treatment and/or prevention of an infection with a HIV virus.
BACKGROUND OF THE INVENTION Persistent HIV reservoirs lead to the failure of potent antiretroviral therapy to eradicate the virus. Although long life-span quiescent T CD4+ memory cells containing the latent provirus are the major part of this reservoir, there is also a residual virus population in peripheral blood cells. This peripheral blood cell population was shown to be compartmentalized, indicating that there is persistent low-level replication (Delobel, Aids. 2005;19:1739-1750). An important compartment, the monocyte-macrophages, can store infectious virus particles for a long time. The mechanisms governing the biogenesis of these intracellular stores in monocytes-macrophages are still not clear. Some data indicate that HIV assembly takes place at the plasma membrane, while other findings point to the endosomal compartment. These intracellular stores can efficiently infect new cells by cell-to-cell contact, a process that was recently shown to involve the endocytosis of infecting virus particles by the target cell.
HIV budding involves membrane curvature out of the cytoplasm, either within the endosomal lumen or into the extracellular medium. This process occurs physiologically in the cell by intraluminal vesicle budding into multivesicular bodies (MVB) and results in the internalisation and breakdown of membrane proteins, or the back-fusion to deliver the contents of the intraluminal vesicle into the cytoplasm, or the release of the exosome into the extracellular medium. Lipid sorting is a key step in intracellular vesicle trafficking. The lipid lysobisphosphatidic acid (LBPA(BMP)), also called BMP (bis(monoacylglycero)phosphate), is specifically located in the MVB and is necessary for endosome internal budding (Matsuo, Science. 2004;303:531-534). LBPA(BMP) interacts
with Alix, an ESCRT-associated protein that also binds HIV. Two of the steps in LBPA (BMP) metabolism, synthesis of its precursor (Shinozaki, Biochemistry. 1999;38:1669- 1675) and its hydrolysis (Ito, J Biol Chem. 2002;277:43674-43681 ), involve a MAFP- sensitive phospholipase A2 (PLA2) activity. MAFP (methyl arachidonyl fluorophosphonate) also inhibits the cytosolic calcium-dependent phospholipase A2 (cPLA2) that plays a major role in signal transduction and is involved in the trafficking of vesicle between membranes. In macrophages, this enzyme is translocated to the membranes of vesicles involved in the endocytosis pathway. PLA2 is also involved in the sorting of cholesterol between intracellular compartments and LBPA (BMP) is functionally associated with cholesterol and influences the cellular distribution of cholesterol. Cholesterol is essential for HIV biogenesis and infectivity. The lipid content of the virus envelope evokes that of lipid rafts and the depletion of cholesterol with methyl^-cyclodextrin reduces the infectivity of HIV. Cells can obtain free cholesterol by the internalization of LDL or by de novo synthesis. Another parameter of cellular lipid homeostasis is the intracellular distribution of cholesterol. High concentrations of progesterone retains cholesterol at the plasma membrane, so preventing its redistribution to intracellular membranes and, hence its esterification. The sterol analog, U18666A ^-(2-Diethylaminoethoxy)androst-5-en-17-one, HCI), is also widely used to modify cholesterol synthesis and distribution, leading to cholesterol accumulation in the MVB compartment (Kobayashi, Nat Cell Biol. 1999;1 :1 13-1 18). U18666A inhibits two enzymes in the cholesterol biosynthesis pathway, squalene open cyclase and C8-C7 isomerase. The inventors have investigated the roles of cholesterol and PLA2 in HIV biogenesis, using U18666A and progesterone to modify the intracellular distribution and metabolism of cholesterol, and using the PLA2 inhibitor MAFP. The inventors evaluated the impact of these agents on the capacity of cells to support direct cell-to-cell HIV transfer. The inventors showed that progesterone and MAFP inhibit the egress of HIV, both involving the MVB compartment.
Prior Art:
Some viruses are known to bear a PLA2 activity. The human cytomegalovirus bears a host-cell derived PLA2 activity which is sensitive to inhibitors of cytosolic PLA2. Such inhibitors induce a decrease in de novo expression of certain viral proteins and of virus
production (Allal, J. Virol. 2004;7717-7726). Besides, sequence analysis has revealed PLA2 motifs in capsid proteins of parvovirus. Mutations reducing PLA2 activity decrease viral infectivity. More precisely, this PLA2 activity is critical for efficient transfer of the viral genome into the nucleus to initiate replication (Zadori, Developmental Cell. 2001 ;291 - 302). Patent application EP 1 ,791 ,858 further describes the use of a modified VP1 -capsid protein of parvovirus B19 having a reduced PLA2 activity for use as a medicament for the treatment of a parvovirus infection. However, no role for a PLA2 activity has ever been shown in the HIV replication cycle. Cholesterol biosynthesis has been shown to be important for the replication of norovirus. Indeed, the inhibition of cholesterol biosynthesis increases the level of norovirus proteins and RNA, whereas inhibitors of ACAT reduce the replication of norovirus (Chang, J. Virol. 2009;8587-8595). However, no effect of the inhibition of cholesterol biosynthesis has been shown on the HIV replication cycle.
TNF synthesis in placental cells is induced by HIV-1 infection that, in an autocrine manner, activates viral replication, because neutralizing anti-TNF antibodies block it. Progesterone is believed to inhibit the induction of TNF synthesis by viral infection and virus or gp-120-induced TNF transcription. Such inhibition leads to a decrease in the production of HIV-1 RNA in placental cells at the concentration found in the placental interface (Munoz, JID 2007;1294-1302). However, no effect of progesterone has been shown on the late phase of the viral cycle.
The international patent application WO 2004/1 12724 teaches that progesterone is an inhibitor of HIV replication, and probably acts as a steroid hormone receptor antagonist that blocks the steroid hormone receptor complex that comprises Rip-1 . Rip-1 is a protein that binds to HIV Vpr and that has been shown to be partially responsible for mediating Vpr activity in the human host cell. WO 2004/1 12724 teaches the use of progesterone to therapeutically treat an individual infected with HIV in order to eliminate, reduce or stabilize viral titer and/or increase or stabilize CD4+ cell counts. WO 2004/1 12724 also teaches the use of progesterone to prevent a high risk individual from becoming infected with HIV. However, WO 2004/1 12724 does not teach that progesterone may interfere with cell to cell transmission of HIV. Cocaine is associated with an increased risk for, and progression of, clinical disease associated with human immunodeficiency virus (HIV) infection. It has been shown that a
selective sigma-1 antagonist, BD1047, can block the effects of cocaine on HIV replication in the huPBL-SCID mouse (Roth, J. Leukoc. Biol. 2005;78:1 198-203). More precisely, this blockage occurs before the viral traduction. However, no effect of this antagonist on the late phase of the viral cycle has been shown.
DESCRIPTION OF THE INVENTION
The inventors have investigated the influence of cellular lipid homeostasis on the spread of HIV between monocyte-macrophage cells, a major component of the HIV reservoir. Altering cholesterol metabolism and distribution, or inhibiting the phospholipase A2 activity, led to an increase in the MVB-specific lysolipid lyso-bis phosphatidic acid (LBPA (BMP)) content and to the formation of large MVB.
The inventors have shown that PLA2 inhibitors and progesterone cause virus to become trapped inside intracellular vesicles, thus reducing the release of HIV to the cell periphery and increasing its intracellular storage (Example 3-6). Moreover, PLA2 inhibitors and progesterone increase the LBPA (BMP) content in the MVB compartment (Example 8) and PLA2 inhibitors enhanced both the total number of MVB and their size (Example 7).
The inventors have finally shown that progesterone and MAFP strongly inhibit HIV proliferation in THP-1 cells and in MDM, and greatly reduce the transfer of the HIV reservoir from MDM to PBL (Example 9-10). Progesterone is hypothesized to act via the Sigma-1 Receptor. Sigma-1 R is a receptor chaperone located in the smooth endoplasmic reticulum. Progesterone is an antagonist of this receptor (Maurice, Pharmacol Ther. 2009;124:195-206), while cocain, which enhances HIV production, is an agonist. PLA2 is involved downstream of the Sigma-1 Rs, and blocking these receptors with progesterone could, at least partly, inhibit PLA2 and so increase the cell LBPA (BMP) content (Figure 7). Thus Sigma-1 Rs could regulate the "cross-talk" between cholesterol, progesterone, and PLA2, and account for the effects described by the inventors.
The inventors have remarkably shown that this increase in LBPA (BMP) content was accompanied by a decrease in virus particles release, the particles being sequestrated within intracellular vesicles. Moreover, the release of HIV from human monocyte-derived
macrophages (MDM) was inhibited as well as the transfer of HIV from MDM to autologous lymphocytes by direct cell-to-cell contact. Thus, compounds inducing LBPA (BMP) accumulation in MVB could represent a new way of altering the HIV reservoir.
Further, the inventors have shown that compounds inducing Lyso-Bis Phosphatidic Acid (LPBA) accumulation in multi-vesicular bodies (MVB) of a cell, in particular progesterone and MAFP, inhibit entry of HIV into a cell (in particular entry which involves cellular uptake by a macropinocytosis mechanism) (Figures 10-12, and Examples 1 1 -12).
Therefore, the present invention pertains to a compound inducing Lyso-Bis Phosphatidic Acid (LPBA) accumulation in multi-vesicular bodies (MVB) of a cell for use for inhibiting i) cell-to-cell transmission of a Human Immunodeficiency Virus (HIV), and/or ii) entry of HIV into a cell (more particularly entry which involves endocytosis, preferably which involves macropinocytosis), in an individual in need thereof. The present invention also relates to a method for inhibiting i) cell-to-cell transmission of a Human Immunodeficiency Virus (HIV), and/or ii) entry of HIV into a cell (more particularly entry which involves endocytosis, preferably which involves macropinocytosis), said method comprises a step wherein an individual in need thereof is administered with an effective amount of a compound inducing Lyso-Bis Phosphatidic Acid (LPBA) accumulation in multi-vesicular bodies (MVB) of a cell.
"Endocytosis" is a process by which cells absorb molecules (such as virus) by engulfing them. The term "macropinocytosis" is intended to mean a biological mechanism which involves the invagination of the cell membrane to form a pocket comprising the virus, said pochet then pinches off into the cell to form a vesicle. The vesicle then travels into the cytosol and fuses with other vesicles such as endosomes and lysosomes. The formation of the pocket occurs in a non-specific manner, then does not need any specific receptor.
In the context of the invention, Human Immunodeficiency Virus (HIV) denotes HIV-1 or HIV-2 of any group (M, including subtypes A-K, and their recombinant forms N, O or P). Preferably HIV is HIV-1 .
It is generally considered that HIV assembly takes place at the plasma membrane, leading to the release of newly synthesized virions in the extracellular compartment and
indirect cell-to-cell transmission. However, other findings point to the endosomal compartment. These intracellular stores can efficiently infect new cells by direct cell-to-cell contact (Gousset, PLoS Pathog. 2008;4:e1000015 ; Groot, Blood; 2008;1 1 1 :4660-4663 ; Sattentau, Nat Rev Microbiol. 2008;6:815-826). These cell-to-cell contacts take place at the interface between an infected cell and an uninfected cell, where a supramolecular structure termed a virological synapse is believed to form. In the case of direct cell-to-cell contacts, the newly synthesized virions are directly transmitted from an infected cell to another cell without between released in the extracellular compartment. The compound of the invention is intended for use for inhibiting direct or indirect cell- to-cell transmission. Preferably, the compound of the invention is intended for use for inhibiting direct cell-to-cell transmission.
HIV budding involves membrane curvature out of the cytoplasm, either within the endosomal lumen or into the extracellular medium. This process occurs physiologically in the cell by intraluminal vesicle budding into multi-vesicular bodies (MVB). MVBs, also known as late endosomes, are mainly spherical, lack tubules, and contain many close- packed luminal vesicles. Markers include RAB7 and RAB9 and mannose 6-phosphate receptors. The inventors have shown that inhibiting the phospholipase A2 activity leads to the formation of large MVB.
The Lyso-Bis Phosphatidic Acid (LBPA (BMP)), also called Bis Mono-acyl-glycero Phosphate (BMP), is a lipid specifically located in the MVB that is necessary for endosome internal budding.
LBPA (BMP) accumulation in multi-vesicular bodies (MVB) may be measured by various methods well-known by one skilled in the art. For instance, it may be quantified by intracellular MVB LBPA (BMP) immuno-labeling using for instance the 6C4 anti-LBPA (BMP) antibody and microscopy or FACS analysis, as described in Example 8. Alternatively, LBPA (BMP) may be separated by two-dimensional thin-layer chromatography followed by an HPLC isolation on Nucleosil-NH2 support and biochemical quantification of its fatty acid content may be performed by gas chromatography.
In a preferred embodiment, an increase in the LBPA (BMP) content in the MVB compartment of at least 10%, 20%, 30%, 40% or 50% in cells treated with the compound compared to untreated cells is indicative of a LBPA (BMP) accumulation in the MVB. In some embodiments, the compound inducing Lyso-Bis Phosphatidic Acid (LPBA) accumulation in multi-vesicular bodies (MVB) of a cell for use for inhibiting cell-to-cell transmission of a HIV in an individual in need thereof is a Phospholipase A2 (PLA2) inhibitor or a Sigma-1 Receptor antagonist. By PLA2 inhibitor is meant a compound that inhibits the activity and/or the expression of the Phospholipase A2. By Sigma-1 Receptor antagonist is meant a compound that inhibits the activity and/or the expression of the Sigma-1 Receptor. Preferably, the inhibitors or antagonists according to the invention are direct inhibitors or antagonists that bind to their targets.
The compound inducing LBPA (BMP) accumulation may be a small molecule, an organic or inorganic compound, a peptide inhibitor, a peptidomimetic, an antibody, a lipid, an antisense, an RNA interference, an aptamer, or a ribozyme blocking PLA2 or Sigma- 1 R activity and/or expression.
In preferred embodiments, said compound is selected from the group consisting of MAFP (methyl arachidonyl fluorophosphonate), ATMK / AACOCF3 (arachidonyl trifluoromethyl ketone), Pyrrolidine-2 (N-{(2S,4R)-4-(Biphenyl-2-ylmethyl-isobutyl-amino)- 1 -[2-(2,4-difluorobenzoyl)-benzoyl]-pyrrolidin-2-ylmethyl}-3-[4-(2,4-dioxothiazolidin-5- ylidenemethyl)-phenyl]acrylamide, HCI), Pyrrophenone (N-[[(2S,4R)-1 -[2-(2,4- difluorobenzoyl)benzoyl]-4-[(triphenylmethyl)thio]-2-pyrrolidinyl]methyl]-4-[(Z)-(2,4-dioxo-5- thiazolidinylidene)methyl]-benzamide), BEL / HELSS (BromoEnolLactone or HaloEnolLactone Suicide Substrate), FKGK1 1 (1 .1 .1 .2.2-pentafluoro-7-phenyl-3- heptanone), Me-INDOXAM (2-(8-((2-Carboxyethyl)oxy)-2-ethyl-3-(o-phenylbenzyl)- indolizin-1 -yl)glyoxylamide), Progesterone, NE100 (N,N-diethyl-2-(4-methoxy-3- phenethyloxyphenyl)ethanamine hydrochloride, N-[2-(4-methoxy-3- phenethyloxyphenyl)ethyl]-N-propylpropan-1 -amine-hydrochloride), BD1063 (1 -[2-(3,4- dichlorophenyl)-ethyl]-4-methylpiperazine dihydrochloride), BD1047 (N-[2-(3,4- dichlorophenylethyl]-N-methyl-2-(dimethylamino)ethylamine dihydrobromide), Haloperidol (4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1 -yl]-1 -(4-fluorophenyl)butan-1 -one) and BMY- 14,802 (1 -(4-fluorophenyl)-4-[4-(5-fluoropyrimidin-2-yl)piperazin-1 -yl]butan-1 -ol).
In a much preferred embodiment, the compound inducing Lyso-Bis Phosphatidic Acid (LPBA) accumulation in multi-vesicular bodies (MVB) is MAFP or progesterone.
In another preferred embodiment, the compound inducing LPBA accumulation in multi-vesicular bodies (MVB) is not progesterone.
Interfering with cell to cell transmission of HIV prevents viral load from increasing. It may also result in a decrease of viral load if the cells infected with HIV are eliminated by the immune system or if an anti-HIV is used in combination with the compound inducing LPBA accumulation in multi-vesicular bodies (MVB).
According to some embodiments, the invention also pertains to a compound inducing Lyso-Bis Phosphatidic Acid (LPBA) accumulation in multi-vesicular bodies (MVB) for use for decreasing the viral load of a patient infected with HIV. The term "viral load" refer to the amount of virus present in an involved body fluid. For example, it can be given in RNA copies per milliliter of blood plasma. Different techniques for measuring the viral load are well-known by the one skilled in the art. These include PCR, RT-PCR, ELISA and/or determination of virus-associated reverse transcriptase (RT) activity. Preferably, the compound inducing LPBA accumulation in multi-vesicular bodies
(MVB) does not interfere or inhibit HIV replication cycle in cells.
The expression "individual in need thereof" is intended for a human or non-human mammal infected or likely to be infected with HIV. Preferably the patient is a human. More preferably, the individual in need of a compound inducing Lyso-Bis Phosphatidic Acid (LPBA) accumulation in multi-vesicular bodies (MVB) of a cell for use for inhibiting cell-to- cell transmission of a HIV is a symptomatic individual suffering from a HIV infection.
A "HIV infection" refers to the condition of an individual who is infected with HIV. HIV infection indifferently denotes an asymptomatic HIV infection or a symptomatic HIV infection including the acquired immunodeficiency syndrome (AIDS), whatever its stage of development. Therefore, according to some embodiment, the individual is a symptomatic individual suffering from AIDS. In another embodiment, the individual is an asymptomatic individual who has been exposed or is at risk of having been exposed to HIV. Such individuals include health care
or other individuals who may have accidentally exchanged blood or other biological fluids with an HIV-infected individual, such as through an accidental needle stick, injuries that occur during emergency medical care, rescue or arrest and unprotected sexual contact. Additionally, the present invention is particularly useful to prevent recurrence of infection in patients who have been previously diagnosed as HIV positive but show no indication of infection.
HIV virus may infect different types of cell including monocytes, macrophages, and lymphocytes. Therefore, in a preferred embodiment the cell wherein the compound of the invention is intended to induce LPBA accumulation in MVB is a monocyte, a macrophage or a lymphocyte. More preferably, the cell is a T lymphocyte. Even more preferably, the cell is a T helper lymphocyte (LT4).
In the context of the invention, inhibiting cell to cell transmission of HIV means inhibiting HIV transmission from a monocyte to a monocyte and/or to a macrophage and/or to a lymphocyte. Inhibiting cell to cell transmission of HIV can also mean inhibiting HIV transmission from a macrophage to a monocyte and/or to a macrophage and/or to a lymphocyte. Alternatively, inhibiting cell to cell transmission of HIV can also mean inhibiting HIV transmission from a lymphocyte to a monocyte and/or to a macrophage and/or to a lymphocyte.
The inventors have shown that progesterone and inhibitors of PLA2 strongly inhibit HIV proliferation in THP-1 cells and in MDM, and greatly reduce the transfer of the HIV reservoir from MDM to PBL (Example 9-10). Therefore, the compound of the invention is preferably for use for inhibiting cell-to-cell transmission of HIV from a monocyte, or a macrophage, or a lymphocyte to a lymphocyte.
The compound of the present invention may be administered as a pharmaceutical composition. Thus, another aspect of the invention pertains to a pharmaceutical composition comprising a compound inducing LPBA accumulation in multi-vesicular bodies of a cell for the treatment and/or prevention of HIV infection.
As used herein, the term "treatment", means the action of reversing, alleviating, inhibiting the progress of the HIV infection, or one or more symptoms of such infection.
In addition to treating HIV-infected individual, the present combination products may be used for preventing HIV infection in high risk individuals who, for example, are suspected of having been exposed to the virus. Pharmaceutical compositions comprising a compound of the invention include all compositions wherein the peptide is contained in an amount effective to achieve the intended purpose. In addition, the pharmaceutical compositions may contain suitable physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
The term "physiologically acceptable carrier" is meant to encompass any carrier, which does not interfere with the effectiveness of the biological activity of the active ingredient and that is not toxic to the host to which is administered. Suitable physiologically acceptable carriers are well known in the art and are described for example in Remington's Pharmaceutical Sciences (Mack Publishing Company, Easton, USA, 1985)., which is a standard reference text in this field. For example, for parenteral administration, the above active ingredients may be formulated in unit dosage form for injection in vehicles such as saline, dextrose solution, serum albumin and Ringer's solution.
Besides the physiologically acceptable carrier, the compositions of the invention can also comprise minor amounts of additives, such as stabilizers, excipients, buffers and preservatives.
The composition of the invention may further comprise a second active principle, in particular an anti-HIV therapeutic agent. When formulated within the same composition, the compound of the invention and the anti-HIV therapeutic agent may have a complementary action.
The compound of the present invention may be administered either as an individual therapeutic agent or in combination with other therapeutic agents, in particular anti-HIV therapeutic agents. Thus, another aspect of the invention pertains to products comprising a compound inducing LPBA accumulation in multi-vesicular bodies of a cell and an anti- HIV agent as combination products for the treatment and/or prevention of HIV infection.
The combination products comprising the compound of the invention and an anti- HIV agent may be formulated as separate pharmaceutical compositions and may be administered sequentially or simultaneously or used separated. An "anti-HIV agent" denotes a compound which leads to decreased HIV replication.
There are different classes of anti-HIV drugs that act at different stages of the HIV life- cycle.
Integrase inhibitors inhibit the enzyme integrase, which is responsible for integration of viral DNA into the DNA of the infected cell. Examples of integrase inhibitors include raltegravir and elvitegravir which is currently under clinical trial.
Reverse transcriptase inhibitors include nucleoside and nucleotide reverse transcriptase inhibitors (NRTI) and non-nucleoside reverse transcriptase inhibitors (NNRTI).
NRTI inhibit reverse transcription by being incorporated into the newly synthesized viral DNA and preventing its further elongation. Abacavir (ABC), emtricitabine (FTC), didanosine (ddl), lamivudine (3TC), stavudine (d4T), zidovudine (AZT) and tenofovir (TDF) are examples of NRTI.
NNRTI inhibit reverse transcriptase directly by binding to the enzyme and interfering with its function. Delavirdine, efavirenz (EFV), nevirapine (NVP), etravirine (ETV) are four currently available agents in this class.
Protease inhibitors (Pis) target viral assembly by inhibiting the activity of protease, an enzyme used by HIV to cleave nascent proteins for final assembly of new virions. Examples of protease inhibitors include atazanavir, darunavir, indinavir, fosamprenavir, lopinavir, nelfinavir, saquinavir, tripanavir and ritonavir.
Entry inhibitors include fusion inhibitors and CCR5 inhibitors. They interfere with binding, fusion and entry of HIV-1 to the host cell by blocking one of several targets. Maraviroc and vicriviroc (which is currently under clinical trial) are CCR5 inhibitors and enfuvirtide is one currently available fusion inhibitor.
Maturation inhibitors inhibit the last step in gag processing in which the viral capsid polyprotein is cleaved, thereby blocking the conversion of the polyprotein into the mature capsid protein. Because these viral particles have a defective core, the virions released consist mainly of non-infectious particles. Two drugs in this class are under investigation, bevirimat and Vivecon.
Therefore, the invention also pertains to products comprising a compound inducing LPBA accumulation in multi-vesicular bodies of a cell and an anti-HIV agent selected from the group consisting of integrase inhibitors, reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, fusion inhibitors, CCR5 inhibitors, and maturation inhibitors as combination products for simultaneous, sequential or separated use for the treatment and/or prevention of an infection with a HIV virus.
According to another embodiment, the invention pertains to a pharmaceutical composition comprising a compound inducing LPBA accumulation in multi-vesicular bodies of a cell and an anti-HIV agent selected from the group consisting of integrase inhibitors, reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, fusion inhibitors, CCR5 inhibitors, and maturation inhibitors. The compound of the present invention may be administered by any means that achieve the intended purpose. For example, administration may be achieved by a number of different routes including, but not limited to subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intracerebral, intrathecal, intranasal, oral, rectal, transdermal, buccal, topical, local, inhalant or subcutaneous use. Parenteral and topical routes are particularly preferred.
Dosages to be administered depend on individual needs, on the desired effect and the chosen route of administration. It is understood that the dosage administered will be dependent upon the age, sex, health, and weight of the recipient, concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. The total dose required for each treatment may be administered by multiple doses or in a single dose.
Generally, multiple administrations are performed. According to preferred embodiments of the invention, the compounds are provided over a course of time in which a therapeutically effective amount of compound is present in the individual's body so as to reduce the viral load to essentially undetectable levels or essentially undetectable levels
such that an asymptomatic individual will not develop symptoms or the onset of such symptoms shall be delayed.
Depending on the intended route of delivery, the compounds may be formulated as liquid (e.g., solutions, suspensions), solid (e.g., pills, tablets, suppositories) or semisolid (e.g., creams, gels) forms.
By "effective amount" is meant an amount sufficient to achieve a concentration of compound which is capable of preventing, treating or slowing down the disease to be treated. Such concentrations can be routinely determined by those of skilled in the art. The amount of the compound actually administered will typically be determined by a physician or a veterinarian, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the subject, the severity of the subject's symptoms, and the like. It will also be appreciated by those of skilled in the art that the dosage may be dependent on the stability of the administered compound.
BRIEF DESCRIPTION OF THE FIGURES Figure 1. Effect of U18666A and progesterone on HIV infection of THP1 cells.
Data are expressed as HIV RNA log10 copies / million viable cells.
(A) As compared to control (■), U18666A (7 μΜ) (▲) was added on day 0 to cells with low (1 :1000, panel A1 ) or high (1 :2, panel A2) infection ratios.
(B) Identical experiments with progesterone (A), 10 μΜ final, added to infected cells (1 :1000 and 1 :2 infection ratios in panel B1 and panel B2 respectively) on day 0, as compared to control (■) .[(*) p<0.01]
Figure 2. Influence of lipid disturbing agents on HIV-1 release and HIV-1 intracellular stores in THP-1 cells.
Infected and uninfected THP-1 cells were mixed in a 1 :1000 ratio and drugs added to the culture each day. The final concentration on day 4 was 20 μΜ for MAFP, 40 μΜ for progesterone (PROG), 28 μΜ for U18666A (U18), 20 μΜ for zidovudine (AZT) and 40 μΜ for lopinavir (LPV).
(A) Cells were counted after staining with Trypan blue and the result expressed as millions of cells per ml. The graph represents the mean of 1 1 independent experiments and the bars the standard error of the mean.
(B) The ATP content was quantified for 75,000 viable cells using the Cell Titer Glo® kit (Promega). The graph represents the mean of 4 independent experiments and the bars the standard error of the mean.
(C) HIV-1 RNA in the culture supernatant was quantified as HIV-1 RNA Iog10 copies / million viable cells. The graph represents the mean of 8 independent experiments and the bars the standard error of the mean. Differences between each drug and the control are significant (p<0.05).
Figure 3. Effect of lipid disturbing agents on HIV-1 production by co-cultures of primary macrophages (MDM).
Monocytes-derived macrophages (MDM) were prepared as described in "Material and Methods", infected by coculture (ratio 1 :100) and treated by repeated additions of the three drugs to reach final concentrations at day 4 of 15 μΜ for MAFP, 30 μΜ for progesterone, 21 μΜ for U18666A.
The HIV-1 RNA in the culture medium was normalized to the signal (relative luminescence units) obtained for viable cells with the Cell Titer Glo ® Promega kit and expressed relative to the control. The graph represents the mean of 5 independent experiments and the bars the standard error of the mean. Differences are significant between MAFP, PROG, U18 and the control (p<0.05).
Figure 4. Effect of methyl arachidonyl fluorophosphonate (MAFP), a cytosolic phospholipase A2 inhibitor, on HIV production by THP1 cells.
Data are expressed as HIV RNA log10 copies / million viable cells.
Cells infected at low (A) or high (B) infection ratios were incubated with 5 μΜ MAFP (A) (added on day 0) as compared to control (■). (Panel A, ratio 1 :1000, p=0.07 on day 8; Panel B, ratio 1 :2, p=0. 10 on day 8).
(C) Effect of repeated additions of MAFP added to the cultures every day (except at day 5) giving concentration ranges of 0.6 μΜ to 35 μΜ. Between day 0 and day 8, MAFP concentration increased of 0.6 μΜ to 4.2 μΜ (·); 2.5 μΜ to 17.5 μΜ (T) and 5 μΜ to 35 μΜ (■). Untreated cells (▲). [(*) p< 0.001]
Figure 5. Effect of HIV infection, U 18666 A, progesterone and PLA2 inhibitor on the MVB compartment of THP1 cells
The integrity of the overall MVB compartment was evaluated, qualitatively by immunofluorescence, and quantitatively by FACS by incubating cells with Rh-PE, a fluorescent lipid that specifically targets the MVBs. Immunofluorescence was examined
with a Zeiss wide-field microscope (objective lens 63X) Bar 10 μηι. Cells were examined on day 4.
(A) Uninfected THP-1 cells
(B-E) Infected (1 :2 ratio) THP-1 cells treated with vehicle (B) or repeated additions of 7 μΜ U18666A (C), 10 μΜ progesterone (D) or 5 μΜ MAFP (E).
(F) Percentage of labeled cells of a representative experiment. Open bars: uninfected cells. Black bars: infected cells (ratio 1 :2).
Figure 6. Effect of progesterone and PLA2 inhibitor on the LBPA (BMP) content of infected THP1 cells
Cells at low infection ratio (1 :1000) were cultured for 4 days in the presence of daily additions of ethanol (vehicle), MAFP (5 μΜ), or progesterone (10 μΜ). After 4 days of coculture, i.e on cells in presence of 20 μΜ MAFP or 40 μΜ progesterone. Cells were then collected by centrifugation and the LBPA (BMP) content in a lipid extract was measured. The LBPA (BMP) content is expressed as nmol/50x106 viable cells. Each type of symbol represents an independent experiment (Expt 1 Δ, Expt 2 +, Expt 3 x).
Figure 7. Effect of progesterone and PLA2 inhibitor on the LBPA (BMP) detected in infected THP1 cells
Cells at low infection ratio (1 :1000) were cultured for 4 days in the presence of daily additions of ethanol (vehicle), MAFP (5 μΜ), or progesterone (10 μΜ). After 4 days of coculture, i.e on cells in presence of 20 μΜ MAFP or 40 μΜ progesterone. Cells were then immunolabeled with anti-LBPA (BMP) antibody and the fluorescent signal quantified on a BD FACS Calibur. Each symbol represents an independent experiment. Data are expressed as mean fluorescence intensity (MFI) (Expt 4 O, Expt 5 O, Expt 6□).
Figure 8. Effect of progesterone and PLA2 inhibitor MAFP on HIV production by cell-to-cell infection of human MDM.
MDM were prepared as described in Example 1 , infected by coculture (ratio 1 :100) and treated by repeated additions (every two days) of 10 μΜ progesterone, 5 μΜ MAFP or 5 μΜ AZT. HIV RNA was measured on day 4 of treatment (i.e at final concentrations of 15 μΜ of MAFP or AZT and 30 μΜ progesterone). HIV RNA was normalized to the signal obtained from viable cells with the Cell Titer Glo ® Promega kit. p < 0.005 for MAFP, progesterone or AZT, versus control.
Figure 9. Effect of MAFP and progesterone on direct cell-to-cell transfer.
A PCR experiment was performed on HIV DNA extracts from unadherent autologous leukocytes cocultivated with MDM, following repeated additions (every two days) of ethanol (CTL), MAFP 5 μΜ or 10 μΜ progesterone and 10 μΜ lopinavir. Quantification of the effect of MAFP and progesterone is expressed as the 2[ delta(deltaCt)l count for a single addition on day 0 (Expts 1 and 2), or for repeated additions (Expts 3-5, p< 0.0001) of MAFP or progesterone, versus control.
Figure 10. Influence of Lipid disturbing agents on endocytosis.
THP-1 cells were treated each day to obtain final concentrations on day 4 of 20 μΜ for MAFP, 40 μΜ for progesterone (PROG) and 28 μΜ for U18666A (U18). Endocytosis was monitored by the internalization of FITC dextran. Histograms represent the fluorescence measured at 4°C (dashed lines) and at 37°C (solid lines). Similar results were obtained in three independent experiments.
Figure 11. Influence of lipid disturbing agents on surface molecules involved in HIV-1 spread.
Infected and uninfected THP-1 cells were mixed in a 1 :1000 ratio and drugs added to the culture each day. The final concentration on day 4 was 20 μΜ for MAFP, 40 μΜ for progesterone (PROG) and 28 μΜ for U18666A (U18). The cells were labeled with anti- CD4, anti-CCR5, anti-CXCR4, anti-LFA-1 and anti- ICAM-1 antibodies and analysed using a BD Biosciences LSRII Flow Cytometer™. The Mean Fluorescence Intensity (MFI) was calculated using the DIVA™ software. The graph represents the mean of 3 independent experiments and the bars the standard error of the mean.
Figure 12. Influence of lipid disturbing agents on the cell content of BMP and on sterol distribution in THP1 monocytes
Infected and uninfected THP-1 cells were mixed in a 1 :1000 ratio and drugs added each day to obtain the final concentrations of MAFP, progesterone (PROG) and U18666A (U18) on day 4. The cells were stained with the 6C4 anti-LBPA (BMP) antibody and analysed by FACS.
(A) BMP quantified by the mean fluorescence intensity (MFI) of the cell population and expressed as percentage of that of the controls. The graph represents the mean of independent experiments and the bars the standard error of the mean (CTL and MAFP: n= 5, CTL and PROG: n=7, CTL and U18: n=8). Differences are significant between PROG or U18 and the control (p<0.05).
(B) Representative FACS profiles for each drug. The percentage of labeled cells and the MFI are shown.
BRIEF DESCRIPTION OF THE SEQUENCES
SEQ ID NO: 1 shows the sequence of a forward primer specific for the gag-LTR sequence SEQ ID NO: 2 shows the sequence of a reverse primer specific for the gag-LTR sequence SEQ ID NO: 3 shows the sequence of a Taqman® probe
SEQ ID NO: 4 shows the sequence of a forward primer specific for the beta-actin gene SEQ ID NO: 5 shows the sequence of a reverse primer specific for the beta-actin gene
EXAMPLES
Example 1 : Materials and Methods
Material
Rhodamine-PE (Rh-PE) [(1 ,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N- (lissamine rhodamine B sulfonyl)] was purchased from Avanti Polar Lipids, Birmingham, Alabama, USA. Progesterone and filipin were supplied by Sigma-Aldrich Chimie S.a.r.l. Lyon, France. MAFP was obtained from Biomol International (Enzo Life Sciences, Villeurbanne, France). Macrophage colony stimulating factor (M-CSF) was purchased from Miltenyi Biotec SAS, Paris, France. QIAamp Viral mini kits and QIAamp DNA blood mini kits were purchased from Qiagen SA, Courtaboeuf, France. RT-PCR kits were from Roche Diagnostics, Meylan, France. Culture media and FITC-dextran (MW 10,000) were supplied by Invitrogen SARL, Cergy Pontoise, France. Lopinavir (LPV) and zidovudine (AZT) were obtained from the NIH Research Reagents Program, Germantown, MD, USA. U18666A ^-(2-Diethylaminoethoxy)androst-5-en-17-one, HCI) was purchased from Sigma. PE-labeled goat anti-mouse IgG antibody was from AbD Serotec, Colmar, France. Anti-LBPA (BMP) antibody was a generous gift from T Kobayashi (Lipid Biology Laboratory, RIKEN Institute, Saitama, Japan). PE-anti-CD206, Pacific blue anti-CD4, APC-anti-CD54 (ICAM-1 ), FITC anti-CD1 1 a (LFA-1 ), PE- anti-184 (CXCR4) and PerCP- Cy5.5 anti-CD195 (CCR5) and compensation beads were obtained from BD biosciences, Le Pont de Claix, France. anti-HIV-1 (KC-57 FITC) from Beckman Coulter, Fullerton, USA.
Cell culture
The human promonocytic THP-1 cells were purchased from the ATCC (ATCC number TIB-202™) and maintained at 5.105 cells/ml in RPMI 1640 supplemented with 10 % heat-inactivated fetal calf serum (10% FCS RPMI).
Peripheral blood mononuclear cells were prepared from buffy coats from healthy donors (Etablissement frangais du sang, Toulouse), plated in 6-well plates (107 cells/well) and incubated for 2 hours at 37°C. Adherent monocytes were washed three times with phosphate-buffered saline (PBS) and cultured for 7 days in RPMI -10% FCS containing 25 ng/ml M-CSF to trigger their differentiation into macrophages (MDM, monocyte-derived macrophages). The differentiation from monocytes to macrophages was monitored by quantifying CD206 by FACS.
The viability of THP-1 cells was analysed by trypan blue staining and that of MDM using the luminescent assay, Cell Titer Glo kit® (Promega). Infection
Infection from virus suspensions. THP-1 cells were infected with the HIVLA| strain and MDM were infected with the HIVBa-i_ strain. This was done by incubating the cells with a titrated suspension of virus for 3 hours at 37°C. The ratio of infection was 10 copies of virus RNA per THP-1 cell and 100 copies per MDM. The cells were then washed 5 times with RPMI and placed in RPMI-10% FCS. The infected THP-1 cell line was maintained by adding 3 ml of uninfected THP-1 cells to 20 ml of the infected cell suspension every week.
Infection by coculture of infected and uninfected cells. THP-1 cells infected as described above on day 0, collected by centrifugation, and mixed with uninfected THP-1 at various ratios. Similarly, infected MDM were scraped off the plate, collected, and added to uninfected MDM in a ratio of 1 :100.
For immunofluorescence experiments, a glass coverslip was placed in the wells.
Cell treatments
All the molecules used were dissolved in ethanol (0.1 % final v/v) before adding them to cell cultures.
Treatment of THP1-cells on day 0. Molecules were added to the culture medium containing 1 % FCS of mixed infected and uninfected cells on day 0 to give the indicated final concentration.
Repeated treatment of THP1 cells or MDM. Molecules were added to the culture medium containing 1 % FCS on day 0 to give the indicated final concentration. A fraction of the culture medium was removed and replaced by fresh medium containing the same
amount of test molecules as on day 0. This was done daily for THP1 and every two days for MDM.
Analysis of direct cell-to-cell transfer of HIV
MDM were infected with the HIVBa-i_ strain as described above. Treatment was repeated every two days. Lopinavir (10 μΜ) was added on day 6, and treatment continued for 4 more days. The cells were washed on day 10 incubated with autologous PBL for three hours for contact with MDM containing potentially infectious virus stores. Nonadherent cells were then cultivated for two days in RPMI 10% FCS and their infection evaluated by measuring their HIV DNA content.
HIV quantification
RNA was extracted from 140 μΙ aliquots of culture supernatant using QIAamp viral RNA mini kits (Qiagen) and quantified by real time RT-PCR targeting the LTR gene, as described by Mavigner et al 28. Each run was 45 cycles and the standard curve established from the supernatant of a culture of infected PBMC that had been quantified by a routine automated method (Roche Diagnostics).
DNA was extracted from 106 cells using QIAamp DNA blood mini kits (Qiagen) and quantified by real time PCR targeting a gag-LTR sequence using the following primers, forward 5'-GCCTCAATAAAGCTTGCCTTGA (SEQ ID NO: 1 ) and reverse 5'- GCTCTCTCGACGCAGGACT (SEQ ID NO: 2), and detected with the Taqman® probe 5'- 6Fam-AAGTAGTGTGTGCCCGTCTGTTRTKTGACT-Tamra-3' (SEQ ID NO: 3). Each run was for 45 cycles. The beta-actin gene in each sample was amplified using the primers: forward 5 ' -G ATG AG ATTG G C ATG G CTTT (SEQ ID NO: 4) and reverse 5'- AGAGAAGTGGGGTGGCTTTT (SEQ ID NO: 5), and the products were detected using SyBRgreen®. The HIV/beta-actin DNA ratio was evaluated using the 2[ delta(deltaCt)l count.
Peripheral cellular receptor labeling
Cells (106) that had been treated for 4 days were collected by centrifugation at 105Xg for 5 min, washed in PBS and incubated with PBS 5% human serum, 1 % BSA for 15 min at 4°C. They were then labeled with anti-CD1 1 a, anti-CD195, anti-CD184, anti- CD54 and anti-CD4 antibody for 30 min at 4°C, washed twice in PBS and fixed with a PBS-3.7% PFA solution for 15 min at 4°C. They were finally analysed using a BD Biosciences LSRII Flow Cytometer™ and DIVA™ software. Compensation was done using single-stained compensation beads.
MVB characterization using Rh-PE
Rh-PE labeling: Appropriate amounts of Rh-PE stored in in chloroform:methanol (2:1 ) were dried and suspended in absolute ethanol. The ethanolic solutions were diluted with PBS to give the final concentration (3μΜ) and vortexed vigorously. An aliquot (1 ml) of this mixture was then added to 2.106 cells per condition. These cells had been treated for 4 days and collected by centrifugation. The cells were incubated with Rh-PE for 60 min at 4^. The medium was then removed, the cells extensively washed with PBS containing 3% w/v BSA, and they were incubated in 1 % FCS RPMI for 3 hours at 37°C. A sample of 3.105 labeled cells was washed in PBS and fixed with PFA 3.7% for 20 min.
FACS analysis: labeled cells were analysed using a BD Biosciences FACSCalibur
Flow Cytometer™ and WinMDI™ software.
Wide field microscopy: Washed cells were made to adhere onto L-polylysine-coated microscope slides using a cytospin at 600 rpm 6 min and mounted between sealed glass coverslips and microscope slides with Fluorsave®. They were then examined under a Zeiss wide field microscope on the RIO cellular platform of IFR 150, Toulouse, France.
Lyso bis phosphatidic acid (LBPA (BMP), or bis(monoacylglycero)phosphate [BMP]) quantification
Intracellular MVB LBPA (BMP) labeling with anti-LBPA (BMP) (6C4) and FACS analysis: A sample (106) of cells that had been treated for 4 days were collected by centrifugation (1200 rpm/ 5 min), washed with PBS and fixed by incubation in 3.7% PFA for 20 min at 4^. They were rinsed with PBS and permeabilized by incubation with PBS containing 0.05% saponin and 1 % BSA for 10 min at 4^. The permeablized cells were incubated with Fc blocking reagent for 10 min at 4°C and then with the anti-LBPA (BMP) antibody for 45 min at 4^. The cells were washed again and incubated with PE- conjugated goat anti-mouse antibodies for 45 min at 4°C. Finally, they were washed and analysed in a BD Biosciences FACSCalibur Flow Cytometer™ and WinMDI™ software.
Biochemical quantification of LBPA (BMP): Lipids were extracted from 50.106 cells with chloroform and methanol plus the antioxidant bromohydroxytoluene (BHT). Internal standard (C15 BMP) was added and LBPA (BMP) was measured by chromatography.
Macropinocytosis measurement
Macropinocytosis of THP-1 cells was measured by their uptake of FITC-dextran. Cells (5.105) were incubated with 1 mg/ml FITC-dextran in PBS with 2% FCS for 30 min either at 4°C to block endocytosis and to measure nonspecific binding, or at 37^ to
measure specific uptake. The cells were then washed three times in cold PBS-FCS and analysed using a BD Biosciences FACSCalibur Flow Cytometer™ and FlowJo™ software.
Transmission electron microscopy (TEM)
Cocultures (1 :2 ratio) of infected and uninfected cells were fixed by incubation with
2% glutaraldehyde in 0.1 M Sorensen phosphate buffer (pH = 7.4) for 1 hour and washed with the Sorensen phosphate buffer for 12 hours. These cells were postfixed with 1 % Os04 in Sorensen phosphate buffer (0.05 M Sorensen phosphate, 0.25 M glucose, 1 % Os04) for 1 hour, washed twice with distilled water and prestained with 2% aqueous uranyl acetate for 12 hours. The samples were dehydrated in an ascending ethanol series, embedded in Epon 812 (Electron Microscopy Sciences) and the resin polymerised for 24 hours at 60°C. Ultrathin sections (70 nm thick) were cut and mounted on 150 mesh collodion-coated copper grids and poststained with 3% uranyl acetate in 50% ethanol and with 8.5% lead citrate. The embedded cells were examined in a HU12A Hitachi electron microscope at an accelerating voltage of 75 KV.
Statistical analyses
Graphs were prepared with GraphPad Prism software and statistical analyses were done using StatView software (SAS Institute Inc), including the F-test for comparing variances and Student's f-test for comparing results.
Example 2: HIV infection between monocytic THP1 cells
Because HIV can spread by direct cell-to-cell transmission, the inventors used cocultures of infected and uninfected cells. Infected monocytic THP1 cells were mixed with uninfected ones in various ratios, and the amounts of virus released from the cells over time was measured. The ratios between cells varied from 1 infected cell to 2 uninfected ones ("high infection ratio"), to 1 infected cell to 1000 uninfected ones ("low infection ratio") and reached a plateau on day 4 in all the conditions tested. Cell proliferation was at a steady-state. A very high titer (109 HIV RNA copies / ml culture medium) was obtained with a ratio of 1 :2 and infected cells had to be diluted 1000-fold to obtain a virus titer of 106 RNA copies / ml. The virus titer on day 4 was correlated with the ratio of infected to uninfected cells. Therefore, imaging analyses and LBPA (BMP) measurements were performed on day 4. AZT inhibited the infection by 1 log even at a high infection ratio (1 :2), which is consistent with its effect in vitro.
Electron microscopy indicated that infected cells present on day 4 differed from control uninfected cells in that they contained large amounts of virus that appeared
agglutinated around the cells. There was budding of the virus from the plasma membrane but also virus was present in intracellular vesicles.
Example 3: Modification of cholesterol distribution and viral infection
Intracellular trafficking requires constant changes in the lipid composition of membranes and cholesterol is critical because any impairment of its distribution leads to cellular defects. HIV itself modulates the host cell cholesterol content. The inventors therefore investigated the influence of the cellular cholesterol distribution on HIV production under the experimental conditions outlined in Example 2. U18666A, a cationic amphiphilic compound causes the cholesterol precursors desmosterol and squalene epoxyde to accumulate in endosomes. U18666A had a small, transient effect on day 2 which no longer persisted for longer periods (Figure 1A) even when the ratio of infected /uninfected cells was low (Figure 1 A1 ), or when repeated amounts of U18666A were added. Progesterone causes cholesterol to accumulate at the cell periphery, a different distribution to that caused by U18666A. Progesterone (10 μΜ) added on day 0 inhibited HIV production by one log by THP1 cells in a low ratio of infected/un infected cells (1 :1000) (Figure 1 B), and by about 0.5 log at a high ratio (1 :2) of infected/un infected cells (Figure 1 B2). Adding progesterone each day to a high ratio (1 :2) of infected/un infected cells was no more effective than a single addition at day 0.
The inventors used filipin staining to monitor the distribution of free sterols in infected cells. There was no apparent difference between infected and uninfected cells. The cholesterol in cells cultured at an infected/un infected cells ratio of 1 :1000 was diffusely distributed through the cytoplasm. U18666A increased the accumulation of free cholesterol and its precursors in the intracellular vesicles of these cells, while progesterone caused free cholesterol to accumulate at the cell periphery. Similar results were obtained when cells were cultured at an infected/un infected cell ratio of 1 :2.
Electron microscope examination of cells cultured with U18666A for four days showed that the virus was mainly around the cells, while cells cultured with progesterone showed no accumulation of virus around the cell, but HIV was inside intracellular vesicles. Therefore, the redistribution of cellular cholesterol appears to play a key role in the control of virus release.
Example 4: Influence of MAFP and progesterone on HIV-1 release from THP-1 cells and on HIV-1 intracellular stores
HIV release in the supernatant of cocultures of HIV-infected and non infected THP-1 cells depends on the ratio of these infected to non infected cells, (data not shown).
In order to evaluate the effect of MAFP and progesterone on HIV-1 release and storage, the inventors chose concentrations given preliminary results in the laboratory. Cultures were treated from day 0 to 3 with selected drugs and analyzed at day 4. The cytotoxicity observed after cell staining was not higher for MAFP and progesterone than for antiretroviral treatments already used in HAART, especially lopinavir, and was similar in non infected cultures and in cocultures of infected and uninfected cells mixed in a ratio of 1 :1000 (Figure 2A). Moreover, the ATP content of viable cells was quantified as a control of their global metabolic activity, which was in the same range whatever the treatment was (Figure 2B), and was similar between infected and uninfected cells. In these conditions, HIV-1 release was measured in the culture supernatant by quantification of HIV-1 RNA relatively to the number of viable cells. MAFP and progesterone induced a significant decrease in the HIV-1 released into the culture supernatant on day 4, the virus titer being 0.5 to 0.75 log10 lower than that of the control (Figure 2C).
Example 5: Influence of MAFP and progesterone on HIV-1 release from primary cultures of human monocyte-derived macrophages (MDM)
The effects of MAFP and progesterone on primary human monocyte-derived macrophages (MDM) were confirmed. Compared to control and whatever the treatment was, around 75 % of cells were viable at day 4 of coculture of infected and non infected cells (Figure 3A, left bars). MAFP and progesterone strongly inhibited HIV-1 infection of MDM. Compared to control, 15% and 10% of HIV-1 RNA were retrieved in the cell supernatant for MAFP and progesterone respectively (Figure 3A, right bars). Also, confocal microscopy experiments showed that this decrease of HIV-1 release was associated to the accumulation of BMP in treated cells (data not shown). Like in THP-1 cells, control MDM cells were faintly stained by the anti-BMP antibody, whereas the treated ones had accumulated BMP in intracellular vesicles.
Example 6: Effect of a cPLA2 inhibitor on HIV infection of THP1 cells
PLA2 activity regulates cholesterol-induced Golgi vesiculation and its lipolytic activity enables the cell to generate outward-bending membranes and to regulate membrane trafficking events. The inventors therefore examined the influence of PLA2 inhibition on HIV production by determining the effect of the PLA2 inhibitor, methyl arachidonyl fluoro phosphonate (MAFP) on the spread of HIV in cell cultures. MAFP added to cultures on day 0 inhibited by 0.5 log the HIV production at a low ratio of infected to uninfected cells (1 :1000, Figure 4A) and to a lesser extent at a high infection ratio (Figure 4B). Repeated treatment inhibited the HIV production by 1 log at high ratio of infected cells (Figure 4C);
the most efficient concentrations were 5-35 μΜ. Electron microscopy of cells after 4 days of infection showed that peripheral virus aggregates had almost completely disappeared, whereas there were viruses in the large intracellular compartments, and these compartments contained more virus particles than untreated control infected cells. This suggests that the PLA2 inhibitor caused virus to become trapped inside intracellular vesicles.
Example 7: Effect of the lipid molecules on the MVB compartment of THP1 cells
As treatment with progesterone or MAFP caused the virus to accumulate in the large intracellular compartments, the inventors examined the influence of these molecules on the MVB compartment using Rh-PE labeling. The fluorescent probe Rh-PE accumulates specifically in the MVB compartment when it is added to cells. The Rh-PE in MVBs was quantified by FACS, so providing an estimation of the total volume of the MVBs in cells. In comparison, immunofluorescence microscopy of Rh-PE labeled cells was used to monitor the morphology of MVBs (Figure 5).
FACS quantification showed that HIV-infected cells had more MVBs per cell (Figure 5B) than did control ones (Figure 5A), and the percentage of labeled infected cells was double that of uninfected ones (Figure 5F, "CTL"). FACS quantification showed that neither U18666A nor progesterone modified the total volume of the MVB compartment (Figure 5C-D) from that of untreated infected cells (Figure 5B). MAFP caused the formation of large MVBs, as quantified by FACS (Figure 5E and 5B), and greatly increased the percentage of labeled cells independently of infection (Figure 5F).
Therefore MAFP enhanced both the total number of MVB (Figure 5F) and their size (Figure 5E), which can act as a storage compartment for HIV, as the virus is no longer released from the cell. Although the MVB compartment in infected progesterone-treated cells was not modified (Figure 5D), the effect of progesterone on HIV was similar to that of MAFP; they both reduced the release of HIV to the cell periphery and increased its intracellular storage (Figures 1 and 4).
Example 8: LBPA (BMP) (BMP) content
A change in the MVB content of cells should also lead to changes in the amount of LBPA (BMP) that accumulates in MVB. The inventors used two experimental methods to quantify cellular LBPA (BMP). One was lipid extraction and chromatography and the other was FACS analysis of cells incubated with an anti-LBPA (BMP) antibody (Figures 6-7). Although there was great inter-experimental variability, both methods showed similar
results (Figures 6-7). MAFP increased the LBPA (BMP) content 1 .5-fold to 7-fold, while progesterone produced an even greater increase in the LBPA (BMP) in the MVB compartment, 3-fold to 10-fold (Figure 7). While the increase in LBPA (BMP) produced by progesterone involved the whole cell population, MAFP acted on a subpopulation of cells.
Example 9: Effect of progesterone and PLA2 inhibition on MDM cell infection
The inventors checked the effects of progesterone and MAFP observed on THP1 cells by repeating the tests on human monocyte-derived macrophages and comparing the responses to that of AZT-treated cells (Figure 8). The test compounds were added to the cells every two days (repeated treatment) because MAFP has more effect under these conditions (Figure 4C). Progesterone and MAFP both strongly inhibited HIV proliferation in MDM, as they did in THP-1 cells (Figure 8).
Example 10: Effect of progesterone and PLA2 inhibition on direct HIV cell-to- cell transfer
Thus MAFP and progesterone increase the LBPA (BMP) content of cells, leading to the sequestration of HIV in large intracellular stores that have many of the features of MVB. This is associated with decreased HIV secretion. This retention of HIV in cells prompted us to examine the effects of MAFP and progesterone on the direct transfer of HIV from one cell to another. The inventors first cultured the MDM for six days to ensure that the cells were filled with mature virus particles. The intracellular stores of virus constituted in these first days after infection remain infectious for several weeks. The production of new infectious virus particles was then blocked by incubating the cells with the protease inhibitor lopinavir for four days. These MDM were then cultured with autologous non-adherent leukocytes for three hours at day 10. The inventors thus analyzed the impact of MAFP and progesterone on direct cell-to-cell transfer. Both MAFP and progesterone greatly reduced the transfer of the HIV reservoir from MDM to PBL (Figure 9). Example 11 : Effects of MAFP and progesterone on early endocytosis and on the surface molecules involved in HIV-1 spread
Endocytosis is involved in HIV entry and components of late endosomes are recruited for HIV budding (Benaroch et al., Retrovirology, 7: 29, 2010). The inventors investigatd whether HIV trapping into intracellular compartments upon MAFP or progesterone treatment could result of their effect at some steps of the endocytosis pathway. First, the inventors monitored endocytosis using FITC-dextran. After uptake,
dextrans move through the endocytic track up to the lysosomes and thus, they are good tracers of membrane-impermeable cargo along the endocytic track. The inventors found that endocytosis monitored by dextran was blocked by MAFP or progesterone (Figure 10).
However, inhibition of endocytosis was not accompanied by significant variations of the surface receptors involved in HIV uptake (Figure 1 1 ). Consistent with literature data (Pelchen-Matthews et al., Immunol. Rev., 168:33-49, 1999), HIV-1 infection tended to decrease the expression of CD4, CCR5, CXCR4 as well as LFA-1 and ICAM-1 while, at the opposite, treatments led rather to a slight increase of the surface expression of these markers, both in non infected and infected cells (Figure 1 1 ). This effect of MAFP and progesterone could indicate a blockade on the internalization for recycling of peripheral receptors, consistent with the endocytosis inhibition observed with dextran.
Example 12: Influence of MAFP and progesterone on the BMP content and sterol distribution inTHP-1 cells
To go further in the exploration of the endocytosis pathway, the inventors investigated the variations of BMP content upon MAFP or progesterone treatment, a key lipid of endocytic processes.
To do that, they labeled BMP using a specific monoclonal antibody (6C4) and quantified it by FACS (Figure 12 A, B). The cells were also examined using confocal imaging (data not shown).
For progesterone and U18 treated cells, FACS dot plots show a shift to the high values of fluorescence of the whole population of cells, with a significant increase of the mean fluorescence intensity (MFI) compared to control (p<0.01 , Figure 12A). In MAFP treated cells, a population of highly labeled cells could be evidenced: although MFI was not different from control one, the number of highly labeled cells (defined as cells having a fluorescence exceeding the MFI of control of two standard deviations), was around 3-fold higher than in control (p<0.05), when it was around 7-fold higher for progesterone (p<0.05; Figure 12B). Confocal microscopy showed that control cells were faintly stained by the anti-BMP antibody, whereas the treated cells had accumulated BMP in intracellular vesicles (data not shown).
A functional link has been described between BMP and cholesterol (Chevallier et al., J. Biol. Chem., 283: 27871 -27880, 2008), so filipin staining was used to label free sterols and monitor their distribution. It has been found that free sterols accumulated in intracellular vesicles in THP-1 cells treated with progesterone. In contrast, the whole population of MAFP-treated cells showed faint labeling, as did the control cells (data not
shown). In summary, MAFP triggered the accumulation of BMP into vesicles without vesicular accumulation of filipin-stained sterols including cholesterol.
Therefore, the inventors have shown that MAFP and progesterone inhibit the macropinocytosis. This inhibition might occur by modification of raft formation in the plasma membrane as reported for high concentration of progesterone.
Claims
1 . A compound inducing Lyso-Bis Phosphatide Acid (LPBA) accumulation in multivesicular bodies (MVB) of a cell for use for inhibiting i) cell-to-cell transmission of a Human Immunodeficiency Virus (HIV), and/or ii) entry of HIV into a cell in an individual in need thereof.
2. The compound for the use according to claim 1 , wherein the compound is a Phospholipase A2 (PLA2) inhibitor or a Sigma-1 Receptor antagonist.
3. The compound for the use according to claim 1 or 2, wherein the compound is selected from the group consisting of MAFP (methyl arachidonyl fluorophosphonate), ATMK / AACOCF3 (arachidonyl trifluoromethyl ketone), Pyrrolidine-2 (N-{(2S,4R)-4- (Biphenyl-2-ylmethyl-isobutyl-amino)-1 -[2-(2,4-difluorobenzoyl)-benzoyl]-pyrrolidin-2- ylmethyl}-3-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)-phenyl]acrylamide, HCI),
Pyrrophenone (N-[[(2S,4R)-1 -[2-(2,4-difluorobenzoyl)benzoyl]-4-[(triphenylmethyl)thio]-2- pyrrolidinyl]methyl]-4-[(Z)-(2,4-dioxo-5-thiazolidinylidene)methyl]-benzamide), BEL / HELSS (BromoEnolLactone / HaloEnolLactone Suicide Substrate), FKGK1 1 (1 .1 .1 .2.2- pentafluoro-7-phenyl-3-heptanone), Me-INDOXAM (2-(8-((2-Carboxyethyl)oxy)-2-ethyl-3- (o-phenylbenzyl)-indolizin-1 -yl)glyoxylamide), Progesterone, NE100 (N,N-diethyl-2-(4- methoxy-3-phenethyloxyphenyl)ethanamine hydrochloride, N-[2-(4-methoxy-3- phenethyloxyphenyl)ethyl]-N-propylpropan-1 -amine-hydrochloride), BD1063 (1 -[2-(3,4- dichlorophenyl)-ethyl]-4-methylpiperazine dihydrochloride), BD1047 (N-[2-(3,4- dichlorophenylethyl]-N-methyl-2-(dimethylamino)ethylamine dihydrobromide), Haloperidol (4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1 -yl]-1 -(4-fluorophenyl)butan-1 -one) and BMY- 14,802 (1 -(4-fluorophenyl)-4-[4-(5-fluoropyrimidin-2-yl)piperazin-1 -yl]butan-1 -ol).
4. The compound for the use according to any of claims 1 to 3, wherein the compound is MAFP.
5. The compound for the use according to any of claims 1 to 3, wherein the compound is progesterone.
6. The compound for the use according to any of claims 1 to 5, wherein the individual is a symptomatic individual suffering from a HIV infection, or an asymptomatic individual who has been exposed or is at risk of having been exposed to HIV.
7. The compound for the use according to any of claims 1 to 6, wherein the cell involved in cell-to-cell transmission of a HIV is a monocyte, a macrophage or a lymphocyte.
8. The compound for the use according to any of claims 1 to 7, for use for inhibiting cell-to-cell transmission of HIV from a monocyte, or a macrophage, or a lymphocyte to a lymphocyte.
9. Products comprising a compound inducing Lyso-Bis Phosphatidic Acid (LPBA) accumulation in multi-vesicular bodies (MVB) of a cell and an anti-HIV agent as combination products for simultaneous, sequential or separated use for the treatment and/or prevention of an infection with a HIV virus.
10. A pharmaceutical composition comprising a compound inducing Lyso-Bis Phosphatidic Acid (LPBA) accumulation in multi-vesicular bodies (MVB) of a cell and an anti-HIV agent.
1 1 . The products according to claim 9, or the pharmaceutical composition according to claim 10, wherein the compound inducing LPBA accumulation in MVB of a cell is a Phospholipase A2 (PLA2) inhibitor or a Sigma-1 Receptor antagonist.
12. The products according to claim 9 or 1 1 , or the pharmaceutical composition according to claim 10, wherein the compound inducing LPBA accumulation in MVB of a cell is selected from the group consisting of MAFP (methyl arachidonyl
fluorophosphonate), ATMK / AACOCF3 (arachidonyl trifluoromethyl ketone), Pyrrolidine-2 (N-{(2S,4R)-4-(Biphenyl-2-ylmethyl-isobutyl-amino)-1 -[2-(2,4-difluorobenzoyl)-benzoyl]- pyrrolidin-2-ylmethyl}-3-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)-phenyl]acrylamide, HCI), Pyrrophenone (N-[[(2S,4R)-1 -[2-(2,4-difluorobenzoyl)benzoyl]-4-[(triphenylmethyl)thio]-2- pyrrolidinyl]methyl]-4-[(Z)-(2,4-dioxo-5-thiazolidinylidene)methyl]-benzamide), BEL / HELSS (BromoEnolLactone or HaloEnolLactone Suicide Substrate), FKGK1 1 (1 .1 .1 .2.2- pentafluoro-7-phenyl-3-heptanone), Me-INDOXAM (2-(8-((2-Carboxyethyl)oxy)-2-ethyl-3- (o-phenylbenzyl)-indolizin-1 -yl)glyoxylamide), Progesterone, NE100 (N,N-diethyl-2-(4- methoxy-3-phenethyloxyphenyl)ethanamine hydrochloride, N-[2-(4-methoxy-3- phenethyloxyphenyl)ethyl]-N-propylpropan-1 -amine-hydrochloride), BD1063 (1 -[2-(3,4- dichlorophenyl)-ethyl]-4-methylpiperazine dihydrochloride), BD1047 (N-[2-(3,4- dichlorophenylethyl]-N-methyl-2-(dimethylamino)ethylamine dihydrobromide), Haloperidol (4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1 -yl]-1 -(4-fluorophenyl)butan-1 -one) and BMY- 14,802 (1 -(4-fluorophenyl)-4-[4-(5-fluoropyrimidin-2-yl)piperazin-1 -yl]butan-1 -ol).
13. The products according to any of claim 9 or 1 1 , or the pharmaceutical composition according to claim 10, wherein the compound inducing LPBA accumulation in MVB of a cell is methyl arachidonyl fluoro phosphonate (MAFP) or progesterone.
14. The products according to any of claim 9 or claims 1 1 to 13, or the pharmaceutical composition according to claim 10, wherein the anti-HIV agent is selected from the group consisting of integrase inhibitors, reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, fusion inhibitors, CCR5 inhibitors, and maturation inhibitors.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10306161.0 | 2010-10-25 | ||
EP10306161 | 2010-10-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012055814A1 true WO2012055814A1 (en) | 2012-05-03 |
Family
ID=44146366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2011/068538 WO2012055814A1 (en) | 2010-10-25 | 2011-10-24 | Compound inducing lbpa accumulation for inhibiting cell-to-cell transmission of hiv |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012055814A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8933059B2 (en) | 2012-06-18 | 2015-01-13 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8987237B2 (en) | 2011-11-23 | 2015-03-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US9289382B2 (en) | 2012-06-18 | 2016-03-22 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10052386B2 (en) | 2012-06-18 | 2018-08-21 | Therapeuticsmd, Inc. | Progesterone formulations |
US20180344694A1 (en) * | 2015-08-31 | 2018-12-06 | Diaccurate | Use of indole compounds to stimulate the immune system |
US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10258630B2 (en) | 2014-10-22 | 2019-04-16 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
CN110003303A (en) * | 2019-05-07 | 2019-07-12 | 河南农业大学 | The anti-viral uses of cholesterol transport inhibitor |
US10471148B2 (en) | 2012-06-18 | 2019-11-12 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable PK profile |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0526258A2 (en) * | 1991-08-01 | 1993-02-03 | Eli Lilly And Company | A87689 Compounds, their production and use as phospholipase-A2 inhibitors |
WO2004112724A2 (en) | 2003-06-20 | 2004-12-29 | Viral Genomix, Inc. | Compositions for and methods for treating hiv |
EP1791858A2 (en) | 2004-09-24 | 2007-06-06 | Intercell AG | Modified vp1-capsid protein of parvovirus b19 |
US20090202439A1 (en) * | 2004-08-20 | 2009-08-13 | The Johns Hopkins University | Methods for treatment of angiogenesis |
-
2011
- 2011-10-24 WO PCT/EP2011/068538 patent/WO2012055814A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0526258A2 (en) * | 1991-08-01 | 1993-02-03 | Eli Lilly And Company | A87689 Compounds, their production and use as phospholipase-A2 inhibitors |
WO2004112724A2 (en) | 2003-06-20 | 2004-12-29 | Viral Genomix, Inc. | Compositions for and methods for treating hiv |
US20090202439A1 (en) * | 2004-08-20 | 2009-08-13 | The Johns Hopkins University | Methods for treatment of angiogenesis |
EP1791858A2 (en) | 2004-09-24 | 2007-06-06 | Intercell AG | Modified vp1-capsid protein of parvovirus b19 |
Non-Patent Citations (18)
Title |
---|
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY |
ALLAL, J. VIROL., 2004, pages 7717 - 7726 |
BENAROCH ET AL., RETROVIROLOGY, vol. 7, 2010, pages 29 |
CHEVALLIER ET AL., J. BIOL. CHEM., vol. 283, 2008, pages 27871 - 27880 |
DELOBEL, AIDS, vol. 19, 2005, pages 1739 - 1750 |
DUNCAN ROBIN E ET AL: "Identification and functional characterization of adipose-specific phospholipase A2 (AdPLA).", THE JOURNAL OF BIOLOGICAL CHEMISTRY 12 SEP 2008 LNKD- PUBMED:18614531, vol. 283, no. 37, 12 September 2008 (2008-09-12), pages 25428 - 25436, XP002643856, ISSN: 0021-9258 * |
GEKKER G ET AL: "Cocaine-induced HIV-1 expression in microglia involves sigma-1 receptors and transforming growth factor-beta1", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 6, no. 6, 1 June 2006 (2006-06-01), pages 1029 - 1033, XP024976856, ISSN: 1567-5769, [retrieved on 20060601], DOI: DOI:10.1016/J.INTIMP.2005.12.005 * |
GOUSSET, PLOS PATHOG., vol. 4, 2008, pages E1000015 |
GROOT, BLOOD, vol. 111, 2008, pages 4660 - 4663 |
ITO, J BIOL CHEM., vol. 277, 2002, pages 43674 - 43681 |
KOBAYASHI, NAT CELL BIOL., vol. 1, 1999, pages 113 - 118 |
MATSUO, SCIENCE, vol. 303, 2004, pages 531 - 534 |
MAURICE, PHARMACOL THER., vol. 124, 2009, pages 195 - 206 |
PELCHEN-MATTHEWS ET AL., IMMUNOL. REV., vol. 168, 1999, pages 33 - 49 |
ROTH, J. LEUKOC. BIOL., vol. 78, 2005, pages 1198 - 203 |
SATTENTAU, NAT REV MICROBIOL., vol. 6, 2008, pages 815 - 826 |
SHINOZAKI, BIOCHEMISTRY, vol. 38, 1999, pages 1669 - 1675 |
ZADORI, DEVELOPMENTAL CELL, 2001, pages 291 - 302 |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9248136B2 (en) | 2011-11-23 | 2016-02-02 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10675288B2 (en) | 2011-11-23 | 2020-06-09 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8987237B2 (en) | 2011-11-23 | 2015-03-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8993548B2 (en) | 2011-11-23 | 2015-03-31 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8993549B2 (en) | 2011-11-23 | 2015-03-31 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11103516B2 (en) | 2011-11-23 | 2021-08-31 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9114146B2 (en) | 2011-11-23 | 2015-08-25 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9114145B2 (en) | 2011-11-23 | 2015-08-25 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11793819B2 (en) | 2011-11-23 | 2023-10-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9289382B2 (en) | 2012-06-18 | 2016-03-22 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11110099B2 (en) | 2012-06-18 | 2021-09-07 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11865179B2 (en) | 2012-06-18 | 2024-01-09 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable PK profile |
US10052386B2 (en) | 2012-06-18 | 2018-08-21 | Therapeuticsmd, Inc. | Progesterone formulations |
US11529360B2 (en) | 2012-06-18 | 2022-12-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11166963B2 (en) | 2012-06-18 | 2021-11-09 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8933059B2 (en) | 2012-06-18 | 2015-01-13 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9006222B2 (en) | 2012-06-18 | 2015-04-14 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11033626B2 (en) | 2012-06-18 | 2021-06-15 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8987238B2 (en) | 2012-06-18 | 2015-03-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10471148B2 (en) | 2012-06-18 | 2019-11-12 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable PK profile |
US10639375B2 (en) | 2012-06-18 | 2020-05-05 | Therapeuticsmd, Inc. | Progesterone formulations |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11622933B2 (en) | 2012-12-21 | 2023-04-11 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11497709B2 (en) | 2012-12-21 | 2022-11-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11351182B2 (en) | 2012-12-21 | 2022-06-07 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10835487B2 (en) | 2012-12-21 | 2020-11-17 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10888516B2 (en) | 2012-12-21 | 2021-01-12 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11304959B2 (en) | 2012-12-21 | 2022-04-19 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11065197B2 (en) | 2012-12-21 | 2021-07-20 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11241445B2 (en) | 2012-12-21 | 2022-02-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11123283B2 (en) | 2012-12-21 | 2021-09-21 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11116717B2 (en) | 2012-12-21 | 2021-09-14 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11103513B2 (en) | 2014-05-22 | 2021-08-31 | TherapeuticsMD | Natural combination hormone replacement formulations and therapies |
US10398708B2 (en) | 2014-10-22 | 2019-09-03 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10668082B2 (en) | 2014-10-22 | 2020-06-02 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10258630B2 (en) | 2014-10-22 | 2019-04-16 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10912783B2 (en) | 2015-07-23 | 2021-02-09 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10894035B2 (en) * | 2015-08-31 | 2021-01-19 | Diaccurate | Use of indole compounds to stimulate the immune system |
US20180344694A1 (en) * | 2015-08-31 | 2018-12-06 | Diaccurate | Use of indole compounds to stimulate the immune system |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10532059B2 (en) | 2016-04-01 | 2020-01-14 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
CN110003303A (en) * | 2019-05-07 | 2019-07-12 | 河南农业大学 | The anti-viral uses of cholesterol transport inhibitor |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012055814A1 (en) | Compound inducing lbpa accumulation for inhibiting cell-to-cell transmission of hiv | |
US20170226182A1 (en) | Pd-1 modulation and uses thereof for modulating hiv replication | |
Blanchet et al. | Human immunodeficiency virus-1 inhibition of immunoamphisomes in dendritic cells impairs early innate and adaptive immune responses | |
Gros et al. | Pharmacological regulators of autophagy and their link with modulators of lupus disease | |
Hughes et al. | New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists | |
Lin et al. | The protective effect of hesperetin in osteoarthritis: an in vitro and in vivo study | |
US20130156791A1 (en) | Methods and pharmaceutical compositions for the treatment of hiv-1 infections | |
AU2018201516A1 (en) | Using modulators of CCR5 for treating cancer | |
RU2353357C2 (en) | Ccr5 expression supression compositions and methods of application thereof | |
CN116322665A (en) | Methods and compositions for treating SARS-CoV-2 | |
Kannan et al. | HIV-1 Tat-mediated microglial ferroptosis involves the miR-204–ACSL4 signaling axis | |
US10765664B2 (en) | Treatment of infectious diseases | |
Campbell et al. | CD4+ T cell-mimicking nanoparticles encapsulating DIABLO/SMAC mimetics broadly neutralize HIV-1 and selectively kill HIV-1-infected cells | |
Husby et al. | Phosphatidylserine clustering by the Ebola virus matrix protein is a critical step in viral budding | |
Ruiz et al. | Membrane raft association of the Vpu protein of human immunodeficiency virus type 1 correlates with enhanced virus release | |
US20220249518A1 (en) | Use of ouabain antagonists to inhibit viral infection | |
Husby et al. | The Ebola virus matrix protein clusters phosphatidylserine, a critical step in viral budding | |
AU2012204032B2 (en) | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway | |
US20150051212A1 (en) | Compositions And Methods For Inhibiting Drusen | |
WO2012100835A1 (en) | Methods and compositions for the treatment of aids | |
Oeyen | Closing the gates: The interaction between enveloped viruses and cellular membranes as antiviral strategy | |
EP1631145A2 (en) | P38 kinase inhibitor compositions and methods of using the same | |
Barroso et al. | The effects of HIV and the antiretrovirals on the mitochondria | |
D'amico | HIV-Associated Neurocognitive Disorders: Role of Viral Reservoirs and Lipid Dysregulation | |
Barbaro | The Impact of Opioids, Methamphetamine, and Antiviral Compounds on Mechanisms of HIV Pathogenesis in Human Macrophages |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11773007 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11773007 Country of ref document: EP Kind code of ref document: A1 |